Introduction {#s1}
============

The mesenchymal stroma typically found in normal tissues, which is composed mainly of naïve quiescent fibroblastic cells and their secreted interstitial extracellular matrix (ECM), constitutes a natural tumor suppressive microenvironment that enforces cellular homeostasis ([@bib62]; [@bib86]; [@bib99]; [@bib10]; [@bib21]; [@bib71]; [@bib96]; [@bib5]; [@bib91]). By contrast, the emergence of a desmoplastic (activated) stroma, encompassing fibrotic-like modifications of local and recruited fibroblasts based on tumor interactions with the local microenvironment, has been proposed to play a major role in the development and progression of solid tumors such as pancreatic ductal adenocarcinoma (PDAC) and others ([@bib8]; [@bib45]; [@bib24]; [@bib100]; [@bib36]). Many studies suggest that a fibrotic reaction, such as that seen in pancreatitis, drives a pro-tumorigenic wound-healing response that often precedes tumor development ([@bib95]; [@bib9]). Tumor fibrosis, also known as desmoplasia, has been reported to promote tumorigenesis, providing chemoresistance and shielding tumors from therapeutic agents ([@bib66]; [@bib44]; [@bib53]; [@bib51]). A mechanism of 'stromal reciprocation', involving mutual signaling between tumor and neighboring cancer-associated fibroblasts (CAFs) that promotes tumor growth, has been demonstrated for PDAC ([@bib89]). On the basis of these findings, several studies have attempted complete ablation of desmoplastic stroma as a therapeutic approach to limit tumor growth, but paradoxically, this resulted in the evolution of existing tumors to a more aggressive state, and accelerated rates of tumorigenesis ([@bib68]; [@bib76]). By contrast, the idea of chronically 'normalizing' activated stroma by reprogramming desmoplasia from a tumor-promoting to a tumor-restrictive state has been suggested to bear greater therapeutic promise ([@bib8]; [@bib83]; [@bib48]; [@bib87]; [@bib31]), and the identification of a clinically applicable means to revert desmoplastic stroma is of considerable interest ([@bib87]; [@bib31]; [@bib3]).

Activation of local fibroblastic pancreatic stellate cells and recruited naïve fibroblastic cells during desmoplasia involves their transforming growth factor-beta (TGFβ)-dependent conversion to a myofibroblastic (activated) phenotype ([@bib20]; [@bib61]; [@bib72]; [@bib98]). This phenotype is characterized by the induction of stress fibers and the elevated expression of alpha-smooth muscle actin (αSMA), palladin and other actin-binding proteins, and by the production of an aligned and organized (anisotropic) ECM, with parallel fibers that are rich in discrete fibronectin splice variants (e.g., ED-A) and in type I collagen ([@bib63]; [@bib82]; [@bib41]; [@bib78]; [@bib33]). Despite the strong effect of TGFβ on fibroblast activation and ECM remodeling during epithelial cancer-associated desmoplasia, knowledge of the mechanisms and downstream consequences of this activation remain limited ([@bib39]; [@bib67]). In previous studies, we demonstrated that culturing naïve fibroblasts within CAF-secreted D-ECM is sufficient to induce myofibroblastic conversion ([@bib4]). Compatible with this dynamic ECM-dependent reprogramming, specific cell-matrix receptors, such as integrins α~v~β~5~ and α~5~β~1~, have been identified as regulators of myofibroblastic αSMA ([@bib6]; [@bib58]) and as participants in the maturation of specific types of cell-matrix adhesions that support anisotropic fiber formation ([@bib22]).

In the present work, we first asked whether D-ECM production and the ability of D-ECM to induce myofibroblastic activation can be decoupled and independently regulated. Using a patient-derived human pancreatic model ([@bib55]) as main focus, with supporting data from human renal cancer ([@bib36]) and additional stromal ([@bib4]) models, we found that although TGFβ is needed for production of D-ECM, it is dispensable for subsequent D-ECM-induction of myofibroblastic activation of naïve fibroblasts. We also found that D-ECM controls α~v~β~5~-integrin signaling, which prompts the accumulation of activated, but FAK-independent, α~5~β~1-~integrin pools in specific intracellular vesicles. This D-ECM control of α~v~β~5~-integrin signaling prevents the enrichment of active α~5~β~1~-integrin at the plasma membrane (PM), where α~5~β~1~ activity opposes myofibroblastic activation. Using a novel integrative approach combining multi-colored immunofluorescence and a new quantitative algorithm, we first validated our *in vitro* findings and then applied this process to annotated clinical samples. This defined two readily distinguishable desmoplastic phenotypes that were correlated with markedly distinct clinical outcomes. These phenotypes are based on differences in the stromal localization and levels of either activated SMAD2/3 (indicative of TGFβ signaling) or active α~5~β~1~-integrin and FAK. These signatures help clarify the controversial role of desmoplasia in the progression of cancer. Further, insofar as reversion of D-ECM has been suggested have the potential to confer significant clinical benefit ([@bib87]; [@bib94]; [@bib65]), these data suggest potential therapies to stabilize patient-protective or to revert patient-detrimental stroma.

Results {#s2}
=======

TGFβ is necessary for CAF production of functional anisotropic D-ECM {#s2-1}
--------------------------------------------------------------------

Fibroblasts were isolated from seven PDAC surgical specimens obtained from five different individuals (with four specimens reflecting two matched tumor-normal pairs, one tumor specimen lacking a matched normal control, and two specimens pathologically designated as non-tumor/normal). These fibroblasts were characterized as naïve pancreatic stellate cells or PDAC-associated desmoplastic CAFs on the basis of assessments of the mRNA and protein expression of the myofibroblastic markers palladin and αSMA ([Figure 1A--B](#fig1){ref-type="fig"}). All specimens were used in parallel for subsequent analyses. In primary culture, these fibroblasts produced characteristic ECM ([@bib30]). Desmoplastic CAFs produced anisotropic D-ECM with multi-layered myofibroblastic spindled nuclei and increased levels of stress fiber-localized αSMA reminiscent of myofibroblastic cells *in vivo* ([@bib33]; [@bib73]; [@bib16]; [@bib27]; [@bib46]), whereas fibroblasts derived from normal specimens did not ([Figure 1C](#fig1){ref-type="fig"}). Quantification of ECM fiber alignment provided a robust measure of tumor-dependent fibroblast activation. We used an arbitrary quantitative threshold of at least 55% of fibers oriented at a spread of 15° from the mode angle as indicative of D-ECMs that had been produced by activated CAFs ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}).10.7554/eLife.20600.003Figure 1.Characterization of human fibroblastic cells isolated from PDAC surgical samples.Fibroblastic cells were isolated from normal or tumoral surgical samples from PDAC patients. (**A**) Representative indirect immunofluorescent assessments of vimentin-positive and pan-cytokeratin-negative fibroblasts, isolated from PDAC surgical specimens. Harvested cells were probed for desmoplastic markers αSMA and palladin, while the pancreatic cancer cell line, Panc1, was used as an epithelial-to-mesenchymal transduced (EMT) control that is known to express both epithelial and mesenchymal markers. Assorted markers are shown in white while counterstained Hoechst-identified nuclei are shown in yellow. (**B**) The bar chart shows normal vs. desmoplastic mRNAs levels, corresponding to αSMA and palladin obtained by RT-qPCR from the indicated 3D-cultures following ECM production (obtained by confluent culturing of fibroblasts in the presence of ascorbic acid for a period lasting 8 days \[[@bib30]\]) (\*\*p=0.0286). (**C**) Representative images of normal vs. desmoplastic phenotypes after 3D ECM production; comparison of low vs. high αSMA levels (white), heterogeneous/round vs. elongated/spindled nuclei (yellow) and disorganized/isotropic vs. parallel aligned/anisotropic ECMs (magenta) are evident in the representative images. Note that the examples shown corresponds to the matching pair of (naïve vs. desmoplastic) fibroblastic cells that were harvested from surgical samples corresponding to patient \#1 and that this pair of cells was used for all examples provided in figures below, unless otherwise stated.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.003](10.7554/eLife.20600.003)10.7554/eLife.20600.004Figure 1---figure supplement 1.CAFs produce anisotropic D-ECMs.(**A**) Images representative of 3D ECM phenotypes: normal (produced by naïve stellate cells N-ECM) and desmoplastic (produced by CAFs D-ECM). The distributions of ECM fiber angles , measured with Image-J's 'OrientationJ' plug, are represented by the various colors; all were normalized using hue values for common, cyan, mode angle visualization as represented on the bar in the right. (**B**) Curves corresponding to the indicated experimental conditions depicting averaged and variations of angle distributions that were normalized to 0˚ modes. Dotted line areas depict a 15˚ spread from the mode. (**C**) Plotted data depicting summarized percentages of fibers distributed at 15˚angles from the mode corresponding to the indicated experimental conditions. Note that comparison between N-ECMs and D-ECMs showed statistically significant differences with p values smaller than 0.0001 (\*\*\*\*).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.004](10.7554/eLife.20600.004)10.7554/eLife.20600.005Figure 1---figure supplement 2.TGFβ inhibition disrupts anisotropy of D-ECM devoid of preventing CAF matrix fibrillogenesis.(**A**) TGFβ protein levels from lysates corresponding to 3D normal (N-ECM) and desmoplastic (D-ECM) matrices, produced by naïve fibroblastic stellate cells or CAFs, respectively, in the presence of the small molecule TGFβ1-receptor inhibitor SB431542 (D+TGFβ-i) or vehicle control (D+DMSO), were measured by ELISA. Data were normalized to total protein concentration in intact D-ECMs; results are expressed as arbitrary units (one arbitrary unit; a.u.). Significance values are \*\*\*p=0.0014, \*\*\*\*p\<0.0001. (**B**) ECM fiber angle distributions, measured with Image-J's 'OrientationJ' plug, are represented by the various colors; all were normalized using hue values for common, cyan, mode angle visualization as represented on the bar on the right. Samples represent D-ECMs produced in the presence TGFβ1-receptor blockage (D+TGFβ-i) or vehicle (D+DMSO). Note how TGFβ inhibition causes disorganization of D-ECM (e.g., loss of anisotropic alignment). (**C**) Curves corresponding to the indicated experimental conditions depicting averaged and variations of angle distributions that were normalized to 0˚ modes. Dotted lines depict areas of 15˚ spreads. (**D**) Plotted data depicting summarized percentages of fibers distributed at 15˚angles from the mode corresponding to the indicated experimental conditions. TGFβ blockage during D-ECM production established that alignments were reduced to 47% (\*\*\*\*p\<0.0001; n = 21), rendering ECMs isotropic or disorganized.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.005](10.7554/eLife.20600.005)10.7554/eLife.20600.006Figure 1---figure supplement 3.TGFβ inhibition disrupts N-ECM production by naïve fibroblastic stellate cells.Representative indirect immunofluorescent images of assorted 'unextracted' 3D cultures depicting nuclei (yellow) and ECMs (magenta) produced by naïve fibroblastic stellate cells or CAFs in the presence or absence of TGFβ1-receptor blockage. Note how TGFβ inhibition causes the disorganization of desmoplastic and the ablation of normal ECMs.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.006](10.7554/eLife.20600.006)

To first test if autocrine TGFβ signaling is essential for CAF production of TGFβ that then contributes to the formation of anisotropic D-ECM, we used an ELISA-based approach to measure levels of TGFβ present in D-ECM in comparison to levels found in normal ECM (N-ECM), or in ECM produced by CAFs treated with SB-431542, a small-molecule inhibitor of the TGFβ1 receptor. Levels of TGFβ in D-ECM were \~2 fold higher than in N-ECM or D-ECM produced in the presence of SB-431542 (D+TGFβi in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}). Importantly, following SB-431542 treatment, CAFs produced isotropic ECMs that were phenotypically indistinguishable from intact N-ECMs ([Figure 1---figure supplement 2B--D](#fig1s2){ref-type="fig"}). This result differed from that produced by the treatment of control naïve pancreatic stellate cells with SB-431542, which produced interrupted TGFβ signaling that caused complete loss of fibrillogenesis, resulting in the absence of matrix production ([Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}). Together, these results suggested that the increased TGFβ observed in D-ECM was critical for CAF production of anisotropic matrices.

Stripping matrix-producing cells from their secreted ECMs produces a residual 'extracted' matrix into which new fibroblasts (e.g., naïve fibroblastic stellate cells) or cancer cells can be seeded ([@bib30]). Using primary human naïve fibroblastic cells, we have previously shown that the residual three-dimensional (3D) D-ECM produced by CAFs is sufficient to induce a myofibroblastic phenotype ([@bib4]). Applying this analysis to pancreatic extracted matrices, we found that D-ECM produced by CAFs in the presence of TGFβ blockade was similar to N-ECM in being incapable of inducing *de novo* myofibroblastic activation (as reflected by increased αSMA stress fiber localization and protein levels) in naïve fibroblastic stellate cells. By contrast,untreated and control treated D-ECM effectively induced such activation ([Figure 2](#fig2){ref-type="fig"}, [Table 1](#tbl1){ref-type="table"}). Similar results were obtained using D-ECM and naïve fibroblastic stellate cells for all five PDAC patients ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}, and [Table 2](#tbl2){ref-type="table"}), suggesting that myofibroblastic activation is a general phenomenon during interactions between naïve pancreatic stellate cells and CAF-produced PDAC-associated D-ECMs. A post-translational effect was implied by the fact that αSMA mRNA levels were comparable in naïve fibroblastic stellate cells cultured in N- vs D-ECM ([Figure 2---figure supplement 2A](#fig2s2){ref-type="fig"}) and because use of cycloheximide to inhibit protein translation did not alter αSMA expression levels ([Figure 2---figure supplement 2B](#fig2s2){ref-type="fig"}), whereas αSMA localization differed ([Figure 2](#fig2){ref-type="fig"}). We also asked whether autocrine TGFβ signaling within naïve stellate cells is necessary for their myofibroblastic activation by D-ECM ([Figure 2---figure supplement 3](#fig2s3){ref-type="fig"} and [Table 3](#tbl3){ref-type="table"}). Growth of these cells in the presence of SB-431542 did not block D-ECM-induced αSMA expression or localization to stress fibers.10.7554/eLife.20600.007Table 1.αSMA stress fiber localization and expression levels in naïve fibroblasts (stellate cells) cultured overnight within assorted ECMs.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.007](10.7554/eLife.20600.007)N-ECMD-ECMD+TGFβiD+DMSOαSMAStress fiber localization25% percentile0.170.820.320.85**Median0.581.000.551.02**75% percentile1.071.120.871.40expression25% percentile0.050.410.520.48**Median0.271.000.730.89**75% percentile0.781.501.141.19[^1][^2][^3][^4][^5][^6][^7][^8]10.7554/eLife.20600.008Table 2.αSMA stress fiber localization and expression levels in assorted naïve pancreatic fibroblasts (stellate cells) cultured overnight within different D-ECMs.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.008](10.7554/eLife.20600.008)(\#X naïve cell) / (\#Y D-ECM)αSMAStress fiber localizationExpression25% percentileMedian75% percentile25% percentileMedian75% percentile**(2)/(1)**0.35**1.00**1.260.65**1.00**1.19**(2)/(2)**0.90**1.15**1.380.87**1.10**1.30**(3)/(2)**0.92**1.08**1.360.86**1.20**1.72**(4)/(1)**0.08**0.85**1.030.79**2.62**3.04**(4)/(5)**0.06**0.83**1.360.29**1.15**2.40**(2)/(5)**0.52**1.24**1.330.60**1.44**2.31**(2)/(1 +TGFβi)**0.00**0.00**0.040.04**0.07**0.10**(2)/(5 +TGFβi)**0.00**0.06**1.200.01**0.14**0.76**(3)/(1 +TGFβi)**0.01**0.06**0.230.01**0.15**0.28**(4)/(5 +TGFβi)**0.11**0.22**0.710.25**0.74**1.66[^9][^10][^11][^12][^13][^14][^15][^16][^17][^18]10.7554/eLife.20600.009Table 3.αSMA stress fiber localization and expression levels in naïve fibroblasts (stellate cells) cultured overnight in the presence or absence of TGFβ inhibitor within intact D-ECMs.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.009](10.7554/eLife.20600.009)**TGFβ-iDMSOαSMAStress fiber localization**25% percentile0.710.72**Median0.961.00**75% percentile1.291.04**expression**25% percentile0.440.49**Median0.620.94**75% percentile1.301.41[^19][^20][^21][^22][^23][^24][^25]10.7554/eLife.20600.010Figure 2.TGFβ is necessary for functional CAF-produced D-ECM.Naïve PDAC fibroblasts were cultured overnight within normal (N-ECM) vs. desmoplastic (D-ECM) ECMs that were produced in the presence or absence of TGFβ1-receptor inhibitor (D + TGFβi) or vehicle control (D + DMSO). All samples were subjected to indirect immunofluorescent labeling of αSMA and counterstained with fluorescently labeled phalloidin to detect actin stress fibers (F-actin). (**A**) Monochromatic images indicating double-labeled staining for αSMA and F-actin. (**B**) Quantification of the levels of localization of αSMA to actin stress fibers (F-actin) from (**A**). (**C**) Pseudo-colored images representing intensity-maps of αSMA levels, with an intensity color bar scale (0--255 intensity tone values) shown to the right. (**D**) Quantification of αSMA intensity from (**C**). Untreated D-ECM conditions were included in all experiments summarized in this figure and served as normalization controls (one arbitrary unit; a.u.). Checkmarks indicate conditions that induce myofibroblastic activation phenotypes. X marks indicate conditions that did not induce myofibroblastic activation. All quantifications and p-values can be found in [Table 1](#tbl1){ref-type="table"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.010](10.7554/eLife.20600.010)10.7554/eLife.20600.011Figure 2---figure supplement 1.Primary CAF-produced D-ECMs induce naïve-to-myofibroblastic activation in normal pancreatic stellate cells.Naïve PDAC fibroblasts or CAFs were isolated from four additional patients and these fibroblasts were cultured overnight within the indicated patient CAF produced matrices, in the presence (D + TGFβi) or absence (D-ECM) of TGFβ1-receptor inhibitor. (**A**) Quantification of the localization of αSMA to actin stress fibers (F-actin) from images of indirect immunofluorescent labeling of αSMA counterstained with fluorescently labeled phalloidin to detect actin stress fibers (F-actin). (**B**) Quantification of images displaying αSMA intensity, from the indicated combinations of fibroblasts and ECMs. Untreated D-ECM conditions from patient \#2 naïve fibroblast re-plated on patient-\#1-derived D-ECM serve as normalization controls (one arbitrary unit; a.u.). Corresponding quantifications and p-values are listed in [Table 2](#tbl2){ref-type="table"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.011](10.7554/eLife.20600.011)10.7554/eLife.20600.012Figure 2---figure supplement 2.D-ECM imparts αSMA post-translational effects during naïve-to-myofibroblastic activation.(**A**) αSMA mRNA levels assessed by RT-qPCR of naïve/normal fibroblasts plated in N- vs. D-ECMs were unaltered. (**B**) Semi-quantitative indirect immunofluorescence showing similar pseudocolors depicting comparable αSMA protein intensity levels of naïve fibroblasts re-plated in D-ECMs comparing vehicle (control) vs. cycloheximide overnight treatments. Intensity levels correspond to the color bar scale shown on the right. Checkmarks indicate conditions that induce myofibroblastic activation phenotypes.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.012](10.7554/eLife.20600.012)10.7554/eLife.20600.013Figure 2---figure supplement 3.TGFβ activity is dispensable for D-ECM-induced naïve-to-myofibroblastic activation.Intact pre-produced **D-ECMs** were seeded overnight with naïve fibroblasts together with TGFβ1-receptor inhibitor (**D + TGFβi**) or vehicle control (**DMSO**). Samples were subjected to indirect immunofluorescent labeling of **αSMA** and counterstained with fluorescently labeled phalloidin to detect actin stress fibers (**F-actin). (A**) Representative images of **αSMA** and **F-actin** (**left** images) and the quantification of **αSMA** at stress fibers (graph on the **right**). (**B**) Pseudocolored images represent intensity maps of **αSMA**, with an intensity color bar scale (0--255 intensity tone values) (**left** images) and the quantification of **αSMA** intensity in the graph (**Right**). Checkmarks indicate that conditions effectively induced the myofibroblastic phenotype. Corresponding quantifications and p-values are summarized in [Table 3](#tbl3){ref-type="table"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.013](10.7554/eLife.20600.013)

Together, these results suggested that TGFβ inhibition during D-ECM production reduces the ability of CAFs to produce ECM that can induce myofibroblastic activation, but that once D-ECM has been deposited by CAFs, TGFβ retained within the D-ECM is subsequently dispensable for D-ECM-induced myofibroblastic activation of naïve stellate cells.

D-ECM controls α~v~β~5~ signaling to regulate active α~5~β~1~-integrin during naïve-to-myofibroblastic activation {#s2-2}
-----------------------------------------------------------------------------------------------------------------

Integrins α~v~β~5~ and α~5~β~1~ have been reported to participate in myofibroblastic activation ([@bib6]; [@bib58]; [@bib22]). We first established that both of these integrin heterodimers were highly abundant, compared to other β-integrins, on the PMs of human naïve pancreatic stellate cells and of PDAC-associated CAFs ([Figure 3A](#fig3){ref-type="fig"}). To determine whether either or both of these heterodimers is essential for D-ECM induction of myofibroblastic conversion, naïve fibroblastic stellate cells were plated overnight on N-ECM or D-ECM in the presence of integrin-inhibitory or negative control antibodies. ALULA, a highly specific α~v~β~5~-integrin-blocking antibody ([@bib88]), eliminated the ability of D-ECM to induce αSMA stress fiber localization (and expression) beyond levels induced by N-ECM ([Figure 3B--E](#fig3){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}). By contrast, mAb16, which specifically blocks human α~5~β~1~-integrin activity ([@bib2]), had limited effects on D-ECM induction of αSMA localization (or expression), with naïve cells undergoing robust myofibroblastic conversion ([Figure 3B--E](#fig3){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}). Intriguingly, combined application of ALULA and mAb16 eliminated the effects of α~v~β~5~-integrin inhibition seen with ALULA alone, with naïve cells undergoing robust myofibroblastic transition similar to that in untreated and IgG controls ([Figure 3B--E](#fig3){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}). This raised the possibility that inhibition of α~5~β~1~ might act downstream of inhibition of α~v~β~5~ in receiving D-ECM signals.10.7554/eLife.20600.014Table 4.αSMA stress fiber localization and expression levels in naïve fibroblasts (stellate cells) cultured overnight within D-ECMs in the presence of integrin functional antibodies.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.014](10.7554/eLife.20600.014)**α~v~β~5~-iα~5~β~1~-iβ~5~+α~5~-iα~5~β~1~-actIgGαSMAStress fiber localization**25% percentile0.140.510.830.410.92**Median0.540.771.110.561.00**75% percentile0.711.201.550.981.00**expression**25% percentile0.110.310.440.080.31**Median0.290.710.900.321.25**75% percentile0.701.272.090.961.95[^26][^27][^28][^29][^30][^31]10.7554/eLife.20600.015Figure 3.Integrin α~v~β~5~ regulates α~5~β~1~ activity thereby maintaining D-ECM-induced naïve-to-myofibroblastic activation.(**A**) An integrin-dependent cell adhesion array test was used to assess the PM expression of integrin heterodimers in primary fibroblasts isolated from normal (white bars) vs. matched tumor tissue (desmoplastic; dark bars). Note that no differences were apparent between the two cell types with regards to levels of α~v~β~5~ and α~5~β~1~ integrins. (**B**) Naïve human pancreatic fibroblastic stellate cells were re-plated onto D-ECMs overnight in the presence of functional blocking anti-α~v~β~5~-integrin (ALULA \[[@bib88]\]; α~v~β~5~-i), functional blocking anti-α~5~β~1~-integrin (mAb16 \[[@bib2]\]; α~5~β~1~-i), combinations of both functional blocking antibodies (β~5~-i + α~5~-i), functional stabilizing anti-α~5~β~1~-integrin (SNAKA51 \[[@bib15]\]; α~5~β~1~-act), or non-immunized isotypic antibodies (IgG). Representative monochromatic images of αSMA- and F-actin stained fibroblasts are shown. (**C**) Quantification of the experiment performed in (**B**). (**D**) Pseudocolored images depicting the intensity of αSMA expression including a color bar scale (0--255 intensity tone values). (**E**) Quantification of (**D**). Note that corresponding quantifications and p-values, for results shown in (**B--E**) are summarized in [Table 4](#tbl4){ref-type="table"}. (**F**) Naïve murine skin fibroblasts were re-plated onto murine D-ECMs (mD-ECM) produced by murine skin squamous cell carcinoma associated CAFs ([@bib4]), and subjected to α~v~β~5~-integrin and α~5~β~1~-integrin inhibitors alone (ALULA: α~v~β~5~-i \[[@bib88]\] and BMA5: α~5~β~1~i) or in combination (β~5~+ α~5~-i). The effects on myofibroblastic activation were measured for αSMA as in (**B**). The red asterisk illustrates the area outlined in red in the magnified insert for the intact (untreated) control. The same magnification is shown for the experimental conditions in the additional panels. As a method of quantifying the percentage of cells showing myofibroblastic features, the percentage of cells that have a stress fiber localized (αSMA) phenotype is shown (\*\*\*\*p\<0.0001). Note that inhibition of α~5~β~1~-integrin effectively reinstituted the mD-ECM-induced phenotype that was lost by inhibition of α~v~β~5~-integrin, just as seen above for the human PDAC system. Checkmarks identify conditions that resulted in myofibroblastic activation, while Xs identify conditions that did not result in myofibroblastic activation. (**G**) Model of D-ECM-induced activation of naïve fibroblasts, dependent on the activity of integrins α~v~β~5~ and α~5~β~1~. Inhibition of α~v~β~5-~ integrin results in release of active α~5~β~1~-integrin, leading to blockade of D-ECM-induced myofibroblastic activation (1^st^ arrow, red X). The activity of α~v~β~5-~ integrin is no longer needed in the absence of α~5~β~1~-integrin activity, suggesting that α~5~β~1~-integrin activity in not necessary for fibroblasts to undergo D-ECM-induced myofibroblastic activation (2^nd^ arrow, green checkmark). Double inhibition of α~v~β~5~-integrin and α~5~β~1~-integrin results in D-ECM myofibroblastic activation, which proposes that inhibition of α~5~β~1~-integrin can overcome or rescue the effects seen under α~v~β~5~-integrin inhibition (3^rd^ arrow, green checkmark). Stabilization of α~5~β~1~-integrin in its active conformation overcomes the inhibitory/regulatory effects imparted by α~v~β~5~-integrin, resulting in ineffective D-ECM-induced myofibroblastic activation (4^th^ arrow, red X). Overall, the model suggests that D-ECM induces α~v~β~5~- integrin activity, which in turn results in the regulation of active α~5~β~1~-integrin, allowing D-ECM-induced myofibroblastic activation (large arrow to the right, green checkmark).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.015](10.7554/eLife.20600.015)10.7554/eLife.20600.016Figure 3---figure supplement 1.Naïve β~5~-integrin KO fibroblasts display stunted D-ECM-induced myofibroblastic activation.(**A**) The CRISPR/CAS9 system was used to generate naïve fibroblastic stellate cell β~5~-integrin knock-out (KO) (β~5~-KO) or control KO (cntrl-KO) lines, whose genoype was confirmed by western blotting. The naïve cntrl-KO and β~5~-KO1 fibroblastic stellate cells were challenged by overnight culture within intact D-ECM and their myofibroblastic features were assessed. (**B**) Samples were subjected to indirect immunofluorescent labeling of αSMA and counterstained with fluorescently labeled phalloidin to detect actin stress fibers (F-actin) and representative monochromatic images are displayed. (**C**) Quantification of αSMA localized at actin stress fibers (F-Actin) from the experiment in (**B**) (\*\*\*p=0.0006; n = 46). (**D**) Pseudocolored images represent intensity map outputs of αSMA, with an intensity color bar scale (0--255 intensity tone values) shown to the right. (**E**) Measured values from (**D**) are summarized in the graph (\*\*\*p=0.0001; n = 46). An experimental condition consisting of naïve cntrl-KO fibroblastic stellate cells cultured in intact D-ECM was included in all experiments; this condition is summarized in this figure and is used for normalization (one arbitrary unit; a.u.). Checkmarks indicate conditions that induce a myofibroblastic activation phenotype, while Xs indicate loss of D-ECM-induced activation.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.016](10.7554/eLife.20600.016)10.7554/eLife.20600.017Figure 3---figure supplement 2.Expression of α~5~-, α~v~- and β~3~-integrins in naïve fibroblastic stellate cells is necessary for D-ECM-induced myofibroblastic activation.(**A**) The CRISPR/CAS9 system was used to generate α~5~-integrin knock-out (α~5~-KO), α~v~-integrin knock-out (α~V~-KO), β~3~-integrin knock-out (β~3~-KO) and control KO (cntrl-KO) naïve fibroblasts, which were confirmed by western blotting. The naïve cntrl-KO and assorted integrin KO fibroblastic stellate cells were challenged by overnight culture within intact D-ECM, and their myofibroblastic features were assessed. (**B**) All samples were subjected to indirect immunofluorescent labeling of αSMA and counterstained with fluorescently labeled phalloidin to detect actin stress fibers (F-actin) and representative monochromatic images are displayed. (**C**) Quantification of αSMA localized at actin stress fibers (F-actin) from the experiment in (**B**) (\*\*\*p=0.0002; \*\*\*\*p\<0.0001). (**D**) Pseudocolored images represent intensity maps of αSMA, with an intensity color bar scale (0--255 intensity tone values) shown to the right. (**E**) Measured values from (**D**) are summarized in the graph (\*\*\*\*p\<0.0001). An experimental condition consisting of naïve cntrl-KO fibroblastic stellate cells cultured in intact D-ECM was included in all experiments summarized in this figure and is used for normalization (one arbitrary unit; a.u., indicated by dotted lines in graphs). X marks indicate loss of D-ECM-induced activation for all tested mutant cells.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.017](10.7554/eLife.20600.017)

To test whether these signaling interactions were specific to human pancreatic cells or also observed in other systems, we used murine skin squamous cell carcinoma associated fibroblasts, which are known to produce myofibroblastic-activating D-ECMs (mD-ECM) ([@bib4]). We cultured naïve murine skin fibroblasts within mD-ECM overnight in the presence of ALULA alone, to inhibit α~v~β~5~-integrin, or in combination with BMA5, to inhibit the activity of murine α~5~β~1~-integrin specifically ([@bib28]). The results of this experiment ([Figure 3F](#fig3){ref-type="fig"}) paralleled those seen with pancreatic stellate cells, suggesting a general mechanism.

To explore the observation that α~v~β~5~-integrin-induced myofibroblastic activation is dispensable upon loss of α~5~β~1~-integrin activity, we directly tested the possibility that α~v~β~5~-integrin negatively regulates α~5~β~1~-integrin to prevent active α~5~β~1~ from blocking D-ECM-induced activation (see model in [Figure 3G](#fig3){ref-type="fig"}). For this, we asked whether stabilizing the activity of α~5~β~1~-integrin could phenocopy α~v~β~5~-integrin inhibition. We found that SNAKA51, an activating antibody that stabilizes the active conformation of α~5~β~1~-integrin ([@bib15]), reduced the ability of D-ECM to induce αSMA stress fiber localization (and expression) in naïve stellate cells ([Figure 3](#fig3){ref-type="fig"} and [Table 4](#tbl4){ref-type="table"}). As an independent approach to simulate ALULA-dependent inhibition of α~v~β~5~-integrin, we used Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-editing to generate a series of naïve stellate cells in which the β~5~, α~5,~ α~v~ or β~3~ (a negative control) integrin subunits were ablated ([Figure 3---figure supplements 1](#fig3s1){ref-type="fig"} and [2](#fig3s2){ref-type="fig"}). Cells lacking the β~5~ subunit had a greatly diminished response to D-ECM, with very limited induction of αSMA stress fiber localization (and expression) ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). By contrast, loss of α~5~-, α~v~- or β~3~-integrin profoundly reduced growth of naïve fibroblasts, yielding slow-growing cells that were also unable to respond to D-ECM. The slow growth and poor condition of the additional KO cells suggests pleiotropic roles for these integrin subunits in supporting cell viability, and thus makes it difficult to draw conclusions. Nonetheless, the results do not rule out a role for α~5~β~1~-integrin activity, regulated by D-ECM control of α~v~β~5~-integrin, that opposes the stimulation of the naïve-to-myofibroblastic transition ([Figure 3G](#fig3){ref-type="fig"}).

Next, we asked whether manipulation of integrin activities in CAFs, as opposed to in naïve stellate cells, could influence their ability to produce functional D-ECM. In contrast to results with TGFβ blockade, neither α~v~β~5~-integrin inhibition (with ALULA) nor stabilization of active α~5~β~1~-integrin (with SNAKA51) altered the anisotropic fiber formation in D-ECM deposited by CAFs ([Figure 4](#fig4){ref-type="fig"}), or the ability of these matrices to induce myofibroblastic activation in naïve fibroblastic stellate cells ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). We also analyzed the ECM produced by CRISPR-edited CAFs lacking specific integrin subunits. In contrast to results with integrin inhibition, CAFs lacking β~5~-integrin or α~5~-integrin subunits had decreased αSMA expression and localization of αSMA to stress fibers. Loss of β~5~ expression also affected levels of D-ECM anisotropy, while CAFs lacking α~5~ failed to produce substantial matrices (matching earlier reports \[[@bib70]; [@bib60]; [@bib29]\]) ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). In addition, loss of α~v~-integrin caused significant reduction in the ability to produce D-ECM, while loss of the negative control, β~3~, had no effect on this phenotype ([Figure 4---figure supplement 3](#fig4s3){ref-type="fig"}). These results suggested that the ability of CAFs to grow and produce functional D-ECMs was selectively affected by loss of α~5~, α~v~ and β~5~ integrin subunits but not by β~3~ loss.10.7554/eLife.20600.018Figure 4.Transient α~v~β~5~-integrin inhibition or α~5~β~1~-integrin stabilization failed to alter CAF production of anisotropic D-ECM.(**A**) Representative indirect immunofluorescent images of 3D D-ECM producing CAFs in the presence of functional blocking anti-α~v~β~5~-integrin (ALULA \[[@bib88]\]; D + α~v~β~5~-i), active conformation stabilizing anti-α~5~β~1~-integrin (SNAKA51 \[[@bib15]\]; D + α~5~β~1~-act.) or non-immunized isotypic antibodies (D + IgG). Spinning disk confocal monochromatic images, obtained following indirect immunofluorescence, show nuclei (Hoechst; yellow), αSMA (white) and ECM (fibronectin; magenta). (**B**) The corresponding ECM fiber angle distributions, determined by Image-J's 'Orientation J' plugin, were normalized using hue values for a cyan mode angle visualization as shown in the bar on the right. (**C**) Corresponding curves depicting experimental-repetition-averaged variations of angle distributions normalized to 0° modes and summarizing the results. Dotted lines correspond to 15° fiber angle spreads. (**D**) Plotted data depicting summarized percentages of fibers distributed at 15° angles from the mode for each experimental condition. The dotted line denotes 55% alignment. Note how none of the treatments seem to have altered the myofibroblastic features of CAFs or their capability to produce anisotropic D-ECMs.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.018](10.7554/eLife.20600.018)10.7554/eLife.20600.019Figure 4---figure supplement 1.D-ECMs produced by CAFs under transient α~v~β~5~-integrin inhibition or stabilization of α~5~β~1~-integrin activity are functionally intact.Naïve fibroblasts were plated onto D-ECMs that were produced in the presence of functional blocking anti-α~v~β~5~-integrin (ALULA \[[@bib88]\]; D + α~v~β~5~-i), active conformation stabilizing anti-α~5~β~1~-integrin (SNAKA51 \[[@bib15]\]; D + α~5~β~1~-act.) or non-immunized isotypic antibodies (D + IgG), and αSMA and actin stress fibers (F-actin) were immunofluorescently labeled. (**A**) Monochromatic images indicative of double-labeled αSMA and F-actin are shown, while levels of total αSMA localized at corresponding stress fibers are plotted in the graph to the right. (**B**) Pseudocolored images represent αSMA intensity values, which are summarized in the graph to the right. Checkmarks indicate conditions that induce a myofibroblastic activation phenotype. Note that D-ECMs that were produced under α~v~β~5~-integrin inhibitory or active α~5~β~1~-integrin stabilizing conditions resulted in no apparent alteration of D-ECM function of CAFs.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.019](10.7554/eLife.20600.019)10.7554/eLife.20600.020Figure 4---figure supplement 2.Loss of β~5~-integrin expression in CAFs impairs D-ECM anisotropy, while expression of α~5~-integrin is imperative for effective ECM fibrillogenesis.Representative western blot of β5-integrin (**A**) and α~5~-integrin (**C**) expression in desmoplastic fibroblasts (CAFs), illustrating the result of CRISPR/CAS9-mediated KO of integrins (A --- β5-KO1 + β5-KO2 and C --- α~5~-integrin α~5~-KO1 + α~5~-KO2) compared to non-targeting gRNA control (cntrl-KO). Histone three was used as a loading control. Representative confocal microscopy images of either control CAF-KO (cntrl-KO) or CAF-β5-integrin-KO2 (β5-KO2) (**B**) or CAF-α~5~-integrin-KO2 (α~5~-KO2) (**D**), depicting αSMA (white) and nuclei (yellow). Inserts show the image-matching ECM fibers (fibronectin, magenta). The images on the right show the corresponding ECM fiber angle distributions as obtained using the Image-J's 'OrientationJ' plug. (**E**) Quantification of the distribution of fiber angles that are within 15° of the mode from (**B**) (\*\*\*\*p\<0.0001). Note that α~5~-KO2 CAFs did not produce matrices that were substantial enough for quantification and were therefore omitted from (**E**).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.020](10.7554/eLife.20600.020)10.7554/eLife.20600.021Figure 4---figure supplement 3.KO of α~V~-integrin, but not β3-integrin, disrupts CAF myofibroblastic features and D-ECM production.Representative western blots of α~V~-integrin (**A**) and β3-integrin (**C**) expression in CAFs, illustrating the result of CRISPR/CAS9 editing of α~V~-integrin (α~V~-KO1 + α~V~-KO2) (**A**) and β3-integrin (β3-KO1 + β3-KO2) (**C**) compared to non-targeting, gRNA, control (cntrl-KO). Histone three was used as a loading control. Representative confocal microscopy images of CAF-α~V~-integrin-KO1 (α~V~-KO1) (**B**) and CAF-β3-integrin-KO1 (β3-KO2) (**D**) depicting αSMA (white) or nuclei (yellow). Inserts show the image-matching ECM fibers (fibronectin, magenta). The images on the right are the corresponding ECMs, which for α~V~-KO1 was not substantial enough to pass the quality thickness test and was therefore omitted from further assessment; for β~3~-KO2, ECM fiber angle distributions shown by pseudocoloring were obtained using Image-J's 'OrientationJ' plug in. (**E**) Quantification of the distribution of fiber angles that are within 15° of the mode shown in (**D**). The dotted line corresponds to the percentage of fiber alignment seen in control KO.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.021](10.7554/eLife.20600.021)

Together, these data indicated that the requirement for specific integrins in the response of naïve fibroblastic cells to D-ECMs differs from the requirement for integrins during CAF production of anisotropic D-ECMs.

FAK-independent α~5~β~1~-integrin activity blocks D-ECM-induced naïve-to-myofibroblastic activation {#s2-3}
---------------------------------------------------------------------------------------------------

Although integrins often signal through focal adhesion kinase (FAK), an increasing number of FAK-independent integrin signaling activities have been observed ([@bib18]; [@bib97]; [@bib101]; [@bib42]). We investigated the role of FAK in D-ECM-induced myofibroblastic activation, treating naïve fibroblastic stellate cells plated in D-ECM with the small molecule FAK inhibitor PF573,228 ([@bib85]). FAK inhibition strongly reduced the ability of these cells to acquire myofibroblastic traits, similar to the result seen with α~v~β~5~-integrin inhibition ([Figure 5](#fig5){ref-type="fig"}). Further, naïve pancreatic stellate cells treated concomitantly with PF573,228 and the α~5~β~1~-integrin-inhibiting mAb16 ([@bib2]) underwent a myofibroblastic conversion, re-localizing and upregulating αSMA ([Figure 5](#fig5){ref-type="fig"}).10.7554/eLife.20600.022Figure 5.FAK-independent α~5~β~1~-integrin activity negatively regulates PDAC D-ECM-induced naïve-to-myofibroblastic activation.Naïve fibroblasts were re-plated onto D-ECMs and challenged with either control conditions (DMSO + IgG), small molecule FAK inhibitor PF573,228 ([@bib85]) (FAK-i) alone or FAK inhibitor in combination with α~5~β~1~-integrin inhibitor (FAK-i + α~5~-i, mAb16 \[[@bib2]\]), and activation of fibroblasts was tested. (**A**) Representative monochromatic images of immunofluorescently labeled αSMA and actin stress fibers (F-actin). Colored asterisks in (**A**) represent areas that are magnified in the corresponding panels to the right. (**B**) Quantification of αSMA at actin stress fibers (F-actin) from the experiment in (**A**) and normalized to DMSO + IgG control (one arbitrary unit; a.u.) (\*\*\*\*p\<0.0001). (**C**) Pseudocolored images represent intensity maps of αSMA, with an intensity color bar scale (0--255 intensity tone values) shown to the right. (**D**) Quantification of αSMA intensity from (**C**) (\*\*\*p=0.0001). Note that the D-ECM-induced phenotype that was lost under FAK inhibition was rescued under α~5~β~1~-integrin co-inhibition (just as for the two integrin co-inhibitions shown in [Figure 3](#fig3){ref-type="fig"}).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.022](10.7554/eLife.20600.022)10.7554/eLife.20600.023Figure 5---figure supplement 1.FAK-independent α~5~β~1~-integrin activity negatively regulates mD-ECM-induced murine naïve-to-myofibroblastic activation.Naïve murine skin fibroblasts were re-plated onto murine D-ECMs ([@bib4]) (mD-ECM) and were treated with PF573,228 (FAK inhibitor) and also subjected to α~v~β~5~-integrin or α~5~β~1~-integrin inhibitors (ALULA --- α~v~β~5~-i ([@bib88]) or BMA5 --- α~5~β~1~i) or IgG control. The effects on naïve-to-myofibroblastic activation were measured in all treated PF573,228 conditions by indirect immunofluorescence of αSMA expression. (**A**) Representative monochromatic images of stress fiber localized αSMA. (**B**) Quantification of the percentage of cells showing myofibroblastic features (stress fiber localized αSMA phenotype %) during the experiment illustrated in (**A**) (\*\*\*p=0.0001). Note that co-inhibition of FAK and α~5~β~1~-integrin effectively reinstituted the mD-ECM-induced phenotype lost as a result of FAK inhibition alone (cnt), just as in the human PDAC stroma system ([Figure 5](#fig5){ref-type="fig"}) and as was the case for the two integrin co-inhibitions shown in [Figure 3](#fig3){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.023](10.7554/eLife.20600.023)10.7554/eLife.20600.024Figure 5---figure supplement 2.α~5~β~1~-integrin inhibition restores mD-ECM-induced naïve-to-myofibroblastic activation in murine FAK^-/-^ skin fibroblasts.FAK null (FAK -/-) naïve murine skin fibroblasts were re-plated onto murine D-ECMs (mD-ECM) subjected to α~v~β~5~-integrin and α~5~β~1~-integrin inhibitors (ALULA --- α~v~β~5~-i \[[@bib88]\] or BMA5 --- α~5~β~1~i). The effects on myofibroblastic activation were measured by indirect immunofluorescence of αSMA expression as before. (**A**) Representative monochromatic images of αSMA expression. (**B**) Quantification of the percentage of cells showing myofibroblastic features (stress fiber localized αSMA phenotype %) during the experiment illustrated in (**A**) (\*\*\*\*p\<0.0001). Note that inhibition of α~5~β~1~-integrin effectively reinstituted the mD-ECM-induced phenotype that was lost as a result of FAK deletion.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.024](10.7554/eLife.20600.024)10.7554/eLife.20600.025Figure 5---figure supplement 3.α~5~β~1~-integrin inhibition restores mD-ECM-induced naïve-to-myofibroblastic in murine FAK-KD skin fibroblasts.Wild-type (WT) or FAK kinase dead (KD) naïve murine skin fibroblasts were re-plated onto murine D-ECMs (mD-ECM) and subjected to α~5~β~1~-integrin inhibitor (BMA5 --- WT α~5~i or KD α~5~i) or IgG control (WT cnt and KD IgG)). The effects on myofibroblastic activation were measured by indirect immunofluorescence of αSMA expression. (**A**) Representative monochromatic images of αSMA expression. (**B**) Quantification of the percentage of cells showing myofibroblastic features (stress fiber localized αSMA phenotype %) during the experiment illustrated in (**A**). Note that inhibition of α~5~β~1~-integrin effectively reinstituted the mD-ECM-induced phenotype that was lost as a result of FAK KD mutation.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.025](10.7554/eLife.20600.025)10.7554/eLife.20600.026Figure 5---figure supplement 4.Ablation of SRC family kinases negates the ability of naïve fibroblasts to respond to mD-ECM.SRC naïve murine skin fibroblasts lacking SRC, YES and FYN (SYF -/-) were re-plated onto murine D-ECMs (mD-ECM) and α~v~β~5~-integrin and α~5~β~1~-integrin inhibitors (ALULA --- α~v~β~5~-i \[[@bib88]\] and BMA5 --- α~5~β~1~i) or IgG control (IgG). The effects on myofibroblastic activation were measured by indirect immunofluorescence of αSMA expression. (**A**) Representative monochromatic images of αSMA expression. (**B**) Quantification of the percentage of cells showing myofibroblastic features (stress fiber localized αSMA phenotype %) during the experiment illustrated in (**A**). Note that inhibition of α~5~β~1~-integrin could not reinstitute the mD-ECM-induced phenotype that was lost in SRC^-/-^ cells.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.026](10.7554/eLife.20600.026)10.7554/eLife.20600.027Figure 5---figure supplement 5.FAK inhibition in conjunction with loss of α~5~-integrin expression in human naïve fibroblasts fails to restore D-ECM-induced myofibroblastic activation.Naïve fibroblastic stellate control KO (cntrl-KO) or α~5~-integrin (α~5~-KO) cells were re-plated within intact D-ECMs and challenged with DMSO as control or with the small molecule FAK inhibitor PF573,228 ([@bib85]) (FAK-i), and the activation of fibroblasts was tested. Representative monochromatic images of αSMA and actin stress fibers (F-actin) were immunofluorescently labeled and are shown. Note that unlike α~5~β~1~-integrin inhibition with mAb16, loss of α~5~-integrin expression did not rescue the myofibroblastic phenotype.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.027](10.7554/eLife.20600.027)

Emphasizing a general mechanism, treatment of naïve murine fibroblasts plated in mD-ECM with PF573,228 blocked acquisition of myofibroblastic traits ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). In naïve murine fibroblasts, concomitant FAK and α~5~β~1~-integrin inhibition with combined PF573,228 and BMA5 significantly increased mD-ECM-induced myofibroblastic conversion when compared with PF573,228 treatment alone, while α~v~β~5~-integrin co-inhibition with FAK did not ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Further, FAK^-/-^ murine naïve fibroblastic cells ([@bib43]) grown in mD-ECM had greatly reduced myofibroblastic activation, which was significantly increased if α~5~β~1~ but not α~v~β~5~ integrin activation was blocked ([Figure 5---figure supplement 2](#fig5s2){ref-type="fig"}). As an additional control to exclude off-target or indirect effects of drug inhibition or FAK KO background compensation, we asked whether murine fibroblasts engineered to express a dominant negative FAK Kinase-Dead mutant (FAK-KD) ([@bib56]) behaved similarly to those with deleted or inhibited FAK, and whether they also recovered responsiveness to D-ECM following inhibition of α~5~β~1~-integrin activity. Immortalized murine fibroblasts overexpressing FAK-KD displayed a lack of myofibroblastic response to mD-ECM compared to the response seen in isogenic hTert immortalized control cells, and again, an efficient rescue of this phenotype was imparted by α~5~β~1~-integrin inhibition ([Figure 5---figure supplement 3](#fig5s3){ref-type="fig"}).

FAK often interacts with SRC family kinases to mediate integrin signaling. To further probe the mechanisms, we evaluated the mD-ECM responsiveness of fibroblasts cells that are genetically null for the SRC family kinases SRC, FYN and YES ([@bib50]). We found that the ablation of SRC family kinases also negated the ability of fibroblasts to respond to mD-ECM. Interestingly, in this context, inhibition of α~5~β~1~-integrin did not restore the mD-ECM-induced myofibroblastic phenotype, indicating non-equivalent functions of FAK and SRC ([Figure 5---figure supplement 4](#fig5s4){ref-type="fig"}). Last, we explored the relationship between FAK and α~5~-integrin expression (as opposed to integrin activity). The ability of the FAK inhibitor to block D-ECM-induced myofibroblastic transition depended on an intact α~5~β~1~ heterodimer, as PF573,228 did not rescue the mD-ECM-induced process that was disrupted in α~5~-KO naïve stellate cells ([Figure 5---figure supplement 5](#fig5s5){ref-type="fig"}).

Together, these results suggested that FAK is essential for D-ECM-induced myofibroblast activation, but dispensable for the α~5~β~1~-integrin inhibition of this process. The data further indicate that genetic ablation of α~5~β~1~-integrin does not recapitulate the result of inhibition of integrin activity in D-ECM responsiveness, perhaps due to additional functional requirements for this integrin in supporting fundamental cell growth.

D-ECM regulates length of 3D-adhesion structures concomitant with α~v~β~5~-integrin-dependent redistribution of active α~5~β~1~-integrin to endosomal vesicles {#s2-4}
--------------------------------------------------------------------------------------------------------------------------------------------------------------

*In vivo*, fibroblasts engage N-ECM through 3D matrix adhesion structures (3D-adhesions) that mediate matrix-dependent homeostasis ([@bib18]). 3D-adhesions are elongated adhesion plaques that depend on α~5~β~1~-integrin activity for their formation and are characterized by encompassing active α~5~β~1~-integrin concomitant with constitutive, albeit low, levels of auto-phosphorylated, activated FAK (pFAK-Y^397^) ([@bib18]). We tested the idea that D-ECM might alter structure, protein composition, or signaling at 3D-adhesions. Naïve stellate cells cultured within D-ECM typically increased the length of 3D-adhesions by \~14% compared to adhesions formed in N-ECM ([Figure 6](#fig6){ref-type="fig"}). While inhibition of α~5~β~1~-integrin with mAb16 was previously shown to cause 3D-adhesion loss ([@bib18]), stabilization of α~5~β~1~-integrin activity using SNAKA51 eliminated the ability of D-ECM to induce 3D-adhesion lengthening. However, α~v~β~5~-integrin inhibition with ALULA did not ([Figure 6](#fig6){ref-type="fig"}). These results separate the requirements for D-ECM-induced α~v~β~5~-integrin regulation of αSMA ([Figure 3](#fig3){ref-type="fig"}) from the lack of requirement for α~v~β~5~-integrin for adhesion reorganization in naïve fibroblastic cells.10.7554/eLife.20600.028Figure 6.D-ECM regulates 3D-adhesion structure length, dependent on α~5~β~1~-integrin activity.(**A**) Indirect immunofluorescent and spinning disc confocal generated images of 3D-adhesions (identified using mAb11) ([@bib18]), formed by naïve fibroblastic cells cultured within N-ECM or D-ECM in the absence (cnt.) or presence of ALULA ([@bib88]) for α~v~β~5~-integrin inhibition (α~v~β~5~-i) or SNAKA52 ([@bib15]) to stabilize α~5~β~1~-integrin activity (α~5~β~1~ act) or IgG as control. (A) The artificially colored structures represent computer-selected internally threshold objects (ITOs) of 3D-adhesion structures. (**B**) Quantification of the length of ITO generated objects from (**A**) (\*\*\*p=0.0026. \*\*\*\*p\<0.0001). Note the significant differences in 3D-adhesion length observed between N-ECM and D-ECM as well as between IgG and SNAKA51 treatments.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.028](10.7554/eLife.20600.028)10.7554/eLife.20600.029Figure 6---figure supplement 1.Naïve fibroblastic cells increase overall levels of active α~5~β~1~-integrin in response to D-ECM.(**A**) Double-labeled images depicting 3D-adhesion (red in overlay; 3D-adh.) and active α~5~β~1~-integrin (green in overlay; α~5~β~1~-act) in naïve fibroblasts cultured overnight in normal-ECMs (N-ECM) or desmoplastic-ECMs (D-ECM). The pseudocolored images on the far right represent semi-quantitative images of maximum reconstructions of active α~5~β~1~-integrin levels (α~5~β~1~-act inten), with a corresponding intensity bar shown on the right. (**B**) Summary of total active α~5~β~1~-integrin levels using median levels on D-ECM for normalization (one arbitrary unit; a.u.) (\*\*\*\*p\<0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.029](10.7554/eLife.20600.029)10.7554/eLife.20600.030Figure 6---figure supplement 2.D-ECMs induce an increase in pFAK levels at 3D-adhesions and redistribution of increased active α~5~β~1~-integrin to locations away from 3D-adhesions.Naïve fibroblasts were cultured within assorted ECMs in the absence (N-ECM or D-ECM) or presence of α~v~β~5~-integrin inhibitor ALULA ([@bib88]) (D-ECM + α~v~β~5~-i) and were stained for adhesion structures, pFAK, and active α~5~β~1~-integrin and the images were quantified. (**A**) Graph depicting active α~5~β~1~-integrin levels localized at 3D-adhesions, normalized to D-ECM median intensities, calculated using SMIA-CUKIE publicly available at <https://github.com/cukie/SMIA>. (**B**) Graph depicting levels of pFAK-Y^397^, calculated using SMIA-CUKIE, localized at 3D-adhesions structures (\*\*\*\*p\<0.0001). (**C**) Graph showing active α~5~β~1~-integrin intensity values, normalized to D-ECM mean intensities and calculated using SMIA-CUKIE, that are localized away from 3D-adhesions (\*\*\*\*p\<0.0001). Note that the D-ECM-induced increases in active α~5~β~1~-integrin, which are evident at locations away from 3D-adhesions, are concomitant with increased 3D-adhesion localized pFAK.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.030](10.7554/eLife.20600.030)10.7554/eLife.20600.031Figure 6---figure supplement 3.D-ECM-induced increase in active α~5~β~1~-integrin is reversed by inhibition of α~v~β~5~-integrin.Summary of results from naïve fibroblasts cultured within assorted ECMs in the absence (N-ECM or D-ECM) or presence of α~v~β~5~-integrin inhibitor ALULA ([@bib88]) (D-ECM + α~v~β~5~-i) and stained for adhesion structures and active α~5~β~1~-integrin. The sizes of pie graphs are relative to SMIA-CUKIE output corresponding to total intensity levels, while relative percentage distributions at 3D-structures (yellow) and away from these structures (light green) are shown. Note that the percentage distributions between locations at and away from 3D-adhesions are relatively unchanged while total intensity levels of active integrin are increased in response to D-ECM.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.031](10.7554/eLife.20600.031)10.7554/eLife.20600.032Figure 6---figure supplement 4.D-ECM induces intracellular accumulation of active α~5~β~1~-integrin.Naïve cells were plated overnight within D-ECM. (**A**) Indirect immunofluorescent images of active α~5~β~1~-integrin (α~5~β~1~-act.; SNAKA51 in green) locations relative to 3D-adhesions (3D-adh.; mAb11 in red), showing a representative cell under permeable vs. non-permeable conditions. The third image (on the right)demonstrates the specificity of active α~5~β~1~-integrin detection when samples were treated with functional blocking anti-α~5~β~1~-integrin antibody, mAb16, under permeable conditions (perm. + α~5~β~1~i). (**B**) Graph summarizes permeable vs. non-permeable values of active α~5~β~1~-integrin from experimental repetitions in which median permeable intensity levels were used for normalization (one arbitrary unit; a.u.) (\*\*\*p=0.0005).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.032](10.7554/eLife.20600.032)10.7554/eLife.20600.033Figure 6---figure supplement 5.D-ECM-induced increase in intracellular α~5~β~1~-integrin activity is regulated by α~v~β~5~-integrin.Summary of results from naïve fibroblasts cultured within assorted ECMs in the absence (N-ECM or D-ECM) or presence of α~v~β~5~-integrin inhibitor ALULA ([@bib88]) (D-ECM + α~v~β~5~-i) and stained, following permeable vs. non-permeable conditions, for adhesion structures and active α~5~β~1~-integrin. The pie graphs depict active α~5~β~1~-integrin fractions localized exogenously on the PM at (non-permeable conditions; yellow or away from (light green) 3D-adhesions, or intracellularly (dark green). Diminished levels of intracellular active α~5~β~1~-integrin are represented by the 'empty' pie wedges (gray). Data were normalized to D-ECM-induced levels obtained under permeable conditions as in [Figure 6---figure supplements 3](#fig6s3){ref-type="fig"}--[4](#fig6s4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.033](10.7554/eLife.20600.033)

Next, we developed a semi-quantitative indirect immunofluorescence analytic method (based on SMIA-CUKIE software; see Methods) to evaluate the total intensity of active α~5~β~1~-integrin, versus its relative intensity, and area distributions related to 3D-adhesion sites. Plating of naïve stellate cells in D-ECM induced a 4-fold increase in active α~5~β~1~-integrin levels compared to plating in N-ECM ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}), but surprisingly, this did not reflect an increase in α~5~β~1~ localized to 3D adhesions ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}) but rather a concentration (\~2 fold) in membrane-proximal regions areas lacking adhesions. To test the idea that D-ECM might affect the recruitment or activation of FAK in 3D adhesions, potentially through control of α~5~β~1~-integrin activation or localization, we also examined the localization of activated FAK (pFAK-Y^397^) to 3D adhesions. Results normalized to levels obtained in D-ECMs (a.u. = 1.0) indicated that D-ECM induced \~2 fold more pFAK-Y^397^ than N-ECM, and that this activated FAK was localized at 3D-adhesions ([Figure 6---figure supplement 2B](#fig6s2){ref-type="fig"}). By contrast, if fibroblasts are cultured in the presence of the α~v~β~5~-integrin inhibitor ALULA, significantly lower levels of pFAK-Y^397^ at 3D-adhesions and active α~5~β~1~-integrin away from 3D-adhesions were observed in cells cultured within D-ECM ([Figure 6---figure supplement 2B--C](#fig6s2){ref-type="fig"}). A summary of results regarding the levels and locations of active α~5~β~1~-integrin is shown in [Figure 6---figure supplement 3](#fig6s3){ref-type="fig"}.

To better refine the location of α~5~β~1~-integrin activation, and taking advantage of the fact that the epitope recognized by SNAKA51 is typically extracellular with PM-localized integrin ([@bib15]), we performed SMIA-CUKIE analysis comparing SNAKA51 levels in permeabilized versus non-permeabilized cells plated on D-ECM versus N-ECM. Non-permeabilized cells had a 5-fold reduction of detectable D-ECM-induced active (SNAKA51-positive) α~5~β~1~-integrin relative to permeabilized cells ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}), indicating that the activated integrin may be rapidly internalized. As a control and to demonstrate the specificity of the active integrin conformation detection, we demonstrated that D-ECM treatment in the presence of the mAb16 inhibitory antibody eliminated all detectable active α~5~β~1~-integrin. In addition, inhibition of α~v~β~5~-integrin, by treatment with ALULA, effectively eliminated the intracellular pool while it considerably increased the amounts of surface-exposed active α~5~β~1~-integrin induced by growth in D-ECM ([Figure 6---figure supplement 5](#fig6s5){ref-type="fig"}).

Generally similar results were obtained in analysis of pancreatic human naïve stellate cells deficient in discrete integrin subunits. Naïve β~5~-integrin KO fibroblastic stellate cells plated within D-ECM had 2.7- and 2.5-fold decreases in total α~5~β~1~-integrin activity and pFAK-Y^397^ levels, respectively, when compared to control KO cells ([Figure 7](#fig7){ref-type="fig"}). Experiments were also conducted using naïve α~5~, α~v~ and β~3~-integrin KO stellate cells as controls. As expected, no detectable α~5~β~1~-integrin activity was observed in α~5~-KO, while only modest decreases in the activity of α~5~β~1~-integrin was observed in α~v~ and β~3~-integrin KO cells grown in intact D-ECM. Interestingly, while a modest pFAK-Y^397^ downregulation was observed in α~5~-KO, there were no appreciable changes in pFAK-Y^397^ in α~v~-KO cells, whereas a small increase in pFAK-Y^397^ was induced by D-ECM in β~3~-integrin KO fibroblastic stellate cells ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). Although results with α~v~- and β~3~-integrin KO did not exclude these integrins from any role in response to D-ECM, these experiments indicated that β~5~-integrin was an effective regulator of both active α~5~β~1~-integrin and pFAK-Y^397^ levels in the response of naïve stellate cells to D-ECM. These results suggest that the observed requirements in naïve fibroblasts for D-ECM-regulated α~v~β~5~-integrin induction of αSMA ([Figure 3](#fig3){ref-type="fig"}) are concomitant with α~v~β~5~-integrin control of redistributions and levels of active α~5~β~1~-integrin and pFAK-Y^397^.10.7554/eLife.20600.034Figure 7.Loss of β5-integrin expression in naïve fibroblasts effectively reduces D-ECM-induced levels of active α~5~β~1~-integrin and pFAK-Y^397^.(**A**) Pseudocolored images showing the intensities of representative indirect immunofluorescence images indicating active α~5~β~1~-integrin (α~5~β~1~-act.) or pFAK from control KO (cntrl KO) or β~5~-integrin KO (β~5~-KO1) naïve fibroblasts. The fibroblasts were cultured overnight within D-ECMs. Intensity scale bars are shown to the right. (**B** and **C**) Quantification of total active α~5~β~1~-integrin (\*\*p=0.0420) (**B**) and pFAK-Y^397^ (\*\*p=0.0246) (**C**) levels of cells from (**A**). Note that both activities that were induced by D-ECM in naïve fibroblasts are lost in β~5~-integrin KO naïve fibroblastic stellate cells.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.034](10.7554/eLife.20600.034)10.7554/eLife.20600.035Figure 7---figure supplement 1.Loss of α~V~- or β~3~-integrins does not significantly reduce overall levels of active α~5~β~1~-integrin that is induced by D-ECM in naïve fibroblasts.(**A**) Pseudocolored images showing the intensities of representative indirect immunofluorescence images indicating active α~5~β~1~-integrin (α~5~β~1~-act.) or pFAK from α~5~-integrin KO (α~5~-KO1), α~V~-integrin KO (α~V~-KO1) or β~3~-integrin KO (β~3~-KO1) naïve fibroblasts cultured overnight with D-ECMs. (**B**) Quantification of total active α~5~β~1~-integrin levels of cells from (**A**). (**C**) Quantifiction of pFAK levels of cells from (**A** (\*\*p=0.0343). Dotted lines in (**B**) and ( denote control KO normalized levels shown in [Figure 7](#fig7){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.035](10.7554/eLife.20600.035)

We next examined whether stabilizing α~5~β~1~-integrin activity with SNAKA51 altered its D-ECM-regulated intracellular relocation. For this, naïve pancreatic stellate cells were cultured overnight in D-ECM in the presence of Alexa 660 fluorophore pre-labeled SNAKA51 or of Alexa 660 pre-labeled isotype antibody control. Cells were then fixed with or without permeabilization and visualized with additional SNAKA51 pre-labeled with a different fluorophore (Alexa 488). SNAKA51 stabilization of α~5~β~1~-integrin activity reduced intracellular, while increasing PM, pools of active α~5~β~1~-integrin when compared to a non-specific IgG treatment control ([Figure 8A](#fig8){ref-type="fig"}). As an independent approach to confirm this result, double immunogold labeling of 3D-adhesions with mAb11 and active α~5~β~1~-integrin with SNAKA51 was analyzed by transmitted electron microscopy of naïve fibroblastic stellate cells cultured within N-ECM, or of fibroblasts cultured in D-ECM while being treated with the α~v~β~5~-integrin inhibiting antibody ALULA or a control antibody. D-ECM induced the intracellular enrichment of the active integrin in discrete punctate structures, which probably reflected endosomes that did not include recognizable clathrin-coated pits. Conversely, inhibition of α~v~β~5~-integrin reduced the accumulation of active α~5~β~1~-integrin intracellular pools, with most signal localized to the PM ([Figure 8B](#fig8){ref-type="fig"}). Supporting this mechanism in an independent model, the relocation of active α~5~β~1~-integrin from intracellular to PM locations following culture within intact D-ECM was also observed in naïve β~5~-integrin KO fibroblastic stellate cells that were compared to control naïve fibroblasts ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}).10.7554/eLife.20600.036Figure 8.D-ECM prompts the internalization or relocation of α~5~β~1~-integrin activity in an α~v~β~5~-integrin-dependent manner.(**A**) Representative indirect immunofluorescent images corresponding to overnight 'chase' incubations with pre-labeled anti-active-α~5~β~1~-integrin antibodies (SNAKA51 \[[@bib15]\]) or IgG controls (blue, --not shown), followed by *de novo* detected active α~5~β~1~-integrin labeling after fixation (α~5~β~1~-act. in green) relative to 3D-adhesion structures (3D-adh. in red) under permeable vs. non-permeable conditions. Note how SNAKA51 treatment but not IgG prompts the relocation of integrin activity to the PM while there is practically no change between permeable and non-permeable active α~5~β~1~-integrin levels. (**B**) Transmitted electron microscopy images of double immunogold-labeled 3D-adhesions (--3D-adh. large particles, \[[@bib18]\]) vs. active α~5~β~1~-integrin (-α~5~β~1~-act. small particles, \[[@bib15]\]), detected in naïve cells cultured within N--ECM vs. D-ECM in the presence or absence of α~v~β~5~-integrin blockage using ALULA ([@bib88]) (αvβ5-i). Both reduction and relocation of active α~5~β~1~-integrin pools are observed. Arrowheads point at random immunogold particles as examples, while the closed arrow indicates the location of a clathrin-coated vesicle.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.036](10.7554/eLife.20600.036)10.7554/eLife.20600.037Figure 8---figure supplement 1.KO of β~5~-integrin in naïve fibroblasts results in a redistribution of D-ECM-induced active α~5~β~1~-integrin from intracellular pools back to the plasma membrane.Transmitted electron microscopy images of double immunogold-labeled 3D-adhesions (--3D-adh. large particles, \[[@bib18]\]) vs. active α~5~β~1~-integrin (-α~5~β~1~-act. small particles, \[[@bib15]\]), detected in naïve control KO (cntrl-KO) or β~5~-integrin KO (β~5~-KO1) fibroblastic stellate cells cultured within D-ECM. The images show a reduction of the total amounts of active α~5~β~1~-integrin and relocation of active α~5~β~1~-integrin pools to the PM in β~5~-integrin KO fibroblasts. The magnified insert depicts an example of intracellular pools of active α~5~β~1~-integrin at what appears to be multi-vesicular endosomes. Note that small particles, indicative of active α~5~β~1~-integrin, seemed to be absent from the clathrin-coated vesicle; these particles are indicated by the closed arrow, while arrowheads point to examples of random immunogold particles.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.037](10.7554/eLife.20600.037)

We directly tested whether the observed intracellular increase in active α~5~β~1~-integrin corresponded to enrichment in discrete endosomal vesicles using a double labeling indirect immunofluorescence approach in naïve control and β~5~-integrin KO pancreatic stellate cells plated into D-ECM. We compared the localization of activated α~5~β~1~-integrin to that of proteins restricted to the early (EEA1 and Rab5) and late (Rab7 and Rab11) endosomal compartments, as well as that of a multivesicular endosomal marker (the tetraspanin CD81). D-ECM induced the partial localization of active α~5~β~1~-integrin to Rab7-, Rab11-, and most clearly, to CD81-positive endosomes in control KO fibroblasts ([Figure 9](#fig9){ref-type="fig"}). By contrast, β5-KO naïve fibroblasts did not similarly relocalize active α~5~β~1~-integrin to these intracellular locations following plating in D-ECM.10.7554/eLife.20600.038Figure 9.Loss of β5-integrin expression in naïve fibroblasts effectively reduces D-ECM-induced relocation of active α~5~β~1~-integrin to late and multivesicular endosomes.Control KO (cntrl-KO) or β~5~-integrin knock-out (β~5~-KO1) naïve fibroblastic stellate cells were cultured overnight in desmoplastic-ECMs (D-ECM), and were subjected to indirect immunofluorescence using SNAKA51 to detect active α~5~β~1~-integrin (α~5~β~1~-act in green) in combination with one of the following endosomal markers shown in red: anti-EEA-1 (for early endosome), anti-Rab5 (for clathrin-mediated endocytosis early endosome), anti-Rab7 (late endosome to be degraded, recycled or rerouted), anti-Rab11 (late endosome to be recycled), or anti-CD81 (multivesicular endosomes). Top panels: confocal images were captured for each double-stained condition to identify the localization of active α~5~β~1~-integrin in relation to the assorted types of endosomes shown in red. Yellow arrowheads point to assorted endosomes and are identically placed in the slightly zoomed monochromatic inserts shown below, which allow better appreciation of the relative locations of the markers vs. those of active α~5~β~1~-integrin. Note that the partial co-localization of active α~5~β~1~-integrin with Rab7, Rab11 and especially with CD81 is lost in the naïve β~5~-KO compared to control KO naive fibroblasts in response to D-ECM.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.038](10.7554/eLife.20600.038)

The increase in levels of active α~5~β~1~-integrin that is also evident in D-ECM-producing CAFs is α~v~β~5~-integrin independent {#s2-5}
--------------------------------------------------------------------------------------------------------------------------------

We complemented the preceding analysis of naïve pancreatic integrin KO fibroblasts using the SMIA-CUKIE algorithm to evaluate active α~5~β~1~-integrin and pFAK-Y^397^ levels in 3D ECM-producing CAFs lacking specific integrin subunits. β~5~-integrin KO CAFs, which have deficiencies in myofibroblastic expression of αSMA and in the formation of anisotropic D-ECM (see [Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}), had no discernible differences in levels of active α~5~β~1~-integrin when compared to control KO CAFs. However, β~5~-integrin KO CAFs cells had notable downregulation of pFAK-Y^397^ expression, suggesting a disturbance in overall integrin signaling that resulted from the loss of this cell-matrix receptor ([Figure 10](#fig10){ref-type="fig"}). In contrast to the observed concomitant regulation of stress-fiber-localized αSMA and of the increased active levels of α~5~β~1~-integrin and FAK in naïve fibroblastic cells responding to D-ECM, a specific mechanistic decoupling between myofibroblastic features, such as αSMA expression and anisotropic D-ECM production, and the regulation of active α~5~β~1~-integrin in CAFs was observed in this analysis of β~5~-integrin KO CAFs. This interpretation was further supported by comparative analysis of 3D ECM production in CAFs lacking other integrin subunits. Loss of α~v~-integrin in CAFs, which led to failure to produce 3D ECMs and to low αSMA expression, did not affect levels of active α~5~β~1~-integrin, whereas loss of the β~3~-integrin subunit, which is associated with cells competent for induction of myofibroblastic features, significantly lowered active α~5~β~1~-integrin levels ([Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}).10.7554/eLife.20600.039Figure 10.Loss of β~5~-integrin in D-ECM-producing CAFs fails to significantly reduce overall levels of active α~5~β~1~-integrin.Representative indirect immunofluorescence images showing active α~5~β~1~-integrin (with SNAKA51 \[[@bib15]\] \[α~5~β~1~-act.\]) or pFAK in control KO (cntrl-KO) or β~5~-integrin KO (β5-KO1) CAFs at the completion of the 3D matrix production process (see Materials and methods). (**B**-**C**) Graphs depicting levels of active α~5~β~1~-integrin (**B**) or pFAK (**C**;\*\*p=0.0465) in control and β~5~-integrin KO CAFs from (**A**). Note that active α~5~β~1~-integrin levels in CAFs were not significantly changed in response to β~5~-integrin loss.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.039](10.7554/eLife.20600.039)10.7554/eLife.20600.040Figure 10---figure supplement 1.Loss of β~3~- but not of α~V~-integrin subunits in D-ECM-producing CAFs alters levels of active α~5~β~1~-integrin.(**A**) Representative indirect immunofluorescence images showing active α~5~β~1~-integrin (with SNAKA51 \[[@bib15]\] \[α~5~β~1~-act.\]) or pFAK corresponding to α~5~-integrin KO (α~5~-KO2), α~V~-integrin KO (α~V~-KO1) or β~3~-integrin KO (β~3~-KO1) CAFs at the conclusion of matrix production (see Materials and methods). (**B**-**C**) Graphs depicting levels of active α~5~β~1~-integrin (**B**) or pFAK (**C**) in control and β~5~-integrin KO CAFs from (**A**) (\*\*\*\*p\<0.0001). Dotted lines in (**B**--**C**) denote control KO CAF normalized levels from [Figure 10](#fig10){ref-type="fig"}. Note that active α~5~β~1~-integrin levels in CAFs were altered in response to β~3~- but not α~V~-integrin loss, whereas levels detected in α~5~-integrin KO CAFs served as background control and were therefore marked as 'not applicable' (**NA**).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.040](10.7554/eLife.20600.040)

The observed differences between the requirement in CAFs for α~v~β~5~ integrin expression during the concomitant regulation of αSMA levels and anisotropic D-ECM production, versus the dispensable nature of α~v~β~5~ for the maintenance of high active α~5~β~1~-integrin levels in these cells, suggests a functional decoupling between the processes.

Fibroblasts isolated from RCC patients also display D-ECM- and integrin-dependent naïve-to-myofibroblastic activation {#s2-6}
---------------------------------------------------------------------------------------------------------------------

To determine whether the relationships between D-ECM, TGFβ and integrins described above pertain to additional human cancers of clinical relevance, we turned to a human renal cell carcinoma (RCC) stroma model ([@bib36]; [@bib33]). RCC stroma is of particular interest because it encompasses a microenvironment that is highly angiogenic and that physically intercalates with cancer cells ([@bib57]), thus distinguishing it from the desmoplasia seen in PDAC. We first demonstrated that renal (r) fibroblasts include an overrepresentation of α~5~β~1~ and α~v~β~5~ integrins relative to alternative β-integrin heterodimers at the plasma membrane ([Figure 11A](#fig11){ref-type="fig"}). Naïve r-fibroblasts expressed low levels of αSMA ([Figure 11B--C](#fig11){ref-type="fig"}) and produced isotropic rN-ECM when compared to rCAF-derived matrices, which produced anisotropic rD-ECM ([Figure 11---figure supplement 1](#fig11s1){ref-type="fig"}). As with PDAC CAFs, treating rCAFs with a TGFβ inhibitor (SB-431542) during ECM production caused cells to produce isotropic matrices ([Figure 11---figure supplement 1](#fig11s1){ref-type="fig"}). Overnight plating of naïve r-fibroblasts in rD-ECM induced the formation of myofibroblastic features such as an increase in stress-fiber-localized αSMA, as compared to cells plated in rN-ECM. Further, the isotropic 3D matrices produced by TGFβR1-inhibited rCAFs failed to induce naïve-to-myofibroblastic activation, whereas TGFβ signaling activity was dispensable in naïve fibroblasts undergoing myofibroblastic activation in response to intact rD-ECM induction.10.7554/eLife.20600.041Figure 11.Renal fibroblasts present a similar profile to pancreatic fibroblasts during matrix production.Fibroblasts were isolated from RCC surgical pathologically normal or tumoral samples, and their ECM-producing phenotypes were assessed after seven days of matrix production. (**A**) An integrin-dependent cell adhesion array test was used to assess the PM expression of integrin heterodimers in primary fibroblasts isolated from normal (white bars) vs. tumoral (dark bars) tissues. Note that no differences were apparent between the two cell types with regards to levels of α~v~β~5~ and α~5~β~1~ integrins. (**B**) Normal vs. desmoplastic mRNAs levels, corresponding to αSMA and palladin (used as an additional myofibroblastic marker as before) were obtained via RT-qPCR from the indicated 3D-cultures following renal ECM (rECM) production, which was achieved via confluent culturing of fibroblasts in the presence of ascorbic acid for a period lasting 8 days ([@bib30]) (\*\*p=0.0286). (**C**) Representative images of normal vs. desmoplastic phenotypes, subsequent to 3D rECM production, are shown; comparison of low vs. high αSMA levels (white), heterogeneous/round vs. elongated/spindled nuclei (yellow) and disorganized/isotropic vs. parallel aligned/anisotropic rECMs (magenta) are evident in the representative images.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.041](10.7554/eLife.20600.041)10.7554/eLife.20600.042Figure 11---figure supplement 1.rD-ECM production by rCAFs is TGFβ-dependent.(**A**) Images representative of the ECM phenotypes of renal normal (rN-ECM) and RCC-associated CAF-derived ECMs (rD-ECM), and of cells treated with small molecule TGFβ1-receptor SB431542 (TGFβ-inhib) or with vehicle (DMSO) during rD-ECM production are shown. ECM fiber angle distributions, measured with Image-J's 'OrientationJ' plug, are represented by the various colors, while all images were normalized using hue values for common, cyan, mode angle visualization as represented in the bar in the right. (**B**) Curves corresponding to the indicated experimental conditions depicting averaged and variations of angle distributions that were normalized to 0˚ modes. Dotted lines indicate 15° spread from the mode. (**C**) Plotted data from (**B**) summarizing percentages of fibers distributed at 15˚angles from the mode in each of the indicated experimental conditions. (\*\*\*\* p\<0.0001, \*\*\*p\<0.0028).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.042](10.7554/eLife.20600.042)10.7554/eLife.20600.043Figure 11---figure supplement 2.rD-ECM-induced renal naïve-to-myofibroblastic activation is reminiscent of pancreatic D-ECM fibroblastic stellate cell activation.Naïve renal fibroblasts were cultured overnight within normal (rN-ECM) or RCC-associated CAF-derived ECMs (rD-ECM). rD-ECMs were produced in the presence of vehicle control (D + DMSO) or TGFβ1-receptor inhibitor (D + TGFβi). Alternatively, naïve cells cultured within rD-ECMs were treated with TGFβ1 inhibitor (TGFβ-i), with vehicle (DMSO), with the function-blocking anti-α~v~β~5~-integrin ALULA([@bib88]) (α~v~β~5~-i), with the function-blocking anti-α~5~β~1~-integrin mAB16 ([@bib2]) (α~5~β~1~-i), with combinations of ALULA + mAb16 (β~5~-i + α~5~-i), with the function-stabilizing anti-active α~5~β~1~-integrin antibody SNAKA51 ([@bib15]) (α~5~β~1~-act), or with corresponding isotype controls (IgG). (**A**) Representative monochromatic images of immunofluorescently labeled αSMA and corresponding actin stress fibers (F-actin). Checkmarks indicate conditions that induce a myofibroblastic activation phenotype in response to rD-ECM. X marks indicate conditions that did not induce myofibroblastic activation. (**B**) Graph depicting measured levels of stress fiber (F-actin) localized αSMA ratios. The results and statistical analysis for this set of experiments are summarized in [Table 5](#tbl5){ref-type="table"}. Note that, while TGFβ inhibition rendered matrices produced by CAFs (D + TGFβi) nonfunctional, naïve renal fibroblasts are effectively activated by rD-ECM in a TGFβ-independent manner (TGFβ-i) that is apparently maintained by the same integrin crosstalk seen in the human PDAC model.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.043](10.7554/eLife.20600.043)10.7554/eLife.20600.044Figure 11---figure supplement 3.FAK-independent α~5~β~1~-integrin activity negatively regulates rD-ECM-induced naïve-to-myofibroblastic activation.Naïve r-fibroblasts were re-plated onto rD-ECMs and challenged with either control conditions (DMSO + IgG), small molecule FAK inhibitor PF573,228 ([@bib85]) (FAK-i) alone or FAK-i in combination with α~5~β~1~-integrin inhibitor (FAK-i + α~5~-i, mAb16 \[[@bib2]\]), and the activation of fibroblasts was tested. (**A**) Representative monochromatic images of immunofluorescently labeled αSMA and actin stress fibers (F-actin). Colored asterisks in (**A**) represent areas that are magnified in the corresponding panels to the right. (**B**) Quantification of αSMA at actin stress fibers (F-actin) from (**A**) normalized to DMSO + IgG control (one arbitrary unit; a.u). (IgG/DMSO vs. FAK-i: \*\*\*\*p=\<0.0001, FAK-i vs. FAK-i + α~5~β~1~-i: \*\*\*p=0.0051).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.044](10.7554/eLife.20600.044)10.7554/eLife.20600.045Figure 11---figure supplement 4.rD-ECM-induced increase in pFAK levels localized at 3D-adhesions are regulated by α~v~β~5~--integrin in naïve renal fibroblasts.Naïve renal fibroblasts were cultured overnight within N-ECM or RCC-associated CAF-derived ECMs (rD-ECM) in the presence or absence of ALULA ([@bib88]) (rD-ECM + α~v~β~5~-i) and 3D-adhesions using mAb11 and pFAK-Y^397^ were detected by indirect immunofluorescence. The resulting SMIA-CUKIE-generated integrated intensities of pFAK-Y^397^ at 3D-adhesions (\*\*\*\*p\<0.0001) are depicted in this graph.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.045](10.7554/eLife.20600.045)10.7554/eLife.20600.046Figure 11---figure supplement 5.rD-ECM regulates 3D-adhesion structure length, dependent on α~5~β~1~-integrin activity.(**A**) Indirect immunofluorescent and spinning disc confocal generated images of 3D-adhesions, identified using mAb11 ([@bib18]), formed by naïve fibroblastic cells cultured within rN-ECM or rD-ECM in the absence (cnt.) or in the presence of ALULA ([@bib88]) for α~v~β~5~-integrin inhibition (α~v~β~5~-i) or of SNAKA51 ([@bib15]) to stabilize α~5~β~1~-integrin activity (α~5~β~1~ act) or of IgG as control. Images were processed using the computer-selected internally threshold objects (ITOs) function of the MetaMorph 7.8.0.0 software. (B) Quantification of the length of ITO-generated objects from (**A**) (\*\*p=0.0492, \*p=0.0928). Note the significant differences in 3D-adhesion length observed between rN-ECM and rD-ECM as well as between IgG and SNAKA51 treatments.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.046](10.7554/eLife.20600.046)10.7554/eLife.20600.047Figure 11---figure supplement 6.Naïve renal fibroblastic cells increase overall levels of active α~5~β~1~-integrin in response to rD-ECM.(**A**) Double-labeled images depicting 3D-adhesion (red in overlay; 3D-adh.) and active α~5~β~1~-integrin (green in overlay; α~5~β~1~-act) in naïve r-fibroblasts cultured overnight in renal normal-ECMs (rN-ECM) or RCC-associated CAF-derived ECMs (rD-ECM). Pseudocolored images at the far right represent semi-quantitative images, maximum reconstructions of active α~5~β~1~-integrin levels (α~5~β~1~-act inten), with a corresponding intensity bar shown on the right. Total active α~5~β~1~-integrin levels were calculated using SMIA-CUKIE, which is publicly available at <https://github.com/cukie/SMIA>. (**B**--**D**) Results are summarized in (**B**), using median levels on rD-ECM for normalization (one arbitrary unit; a.u.) (\*\*\*p=0.0001), in (**C**) using integrated levels of active α~5~β~1~-integrin localized at 3D-adhesions, and in (**D**), using active α~5~β~1~-integrin integrated intensity levels, measured away from 3D-adhesions, in the absence or presence of α~v~β~5~-integrin inhibition (\*\*\*\*p\<0.0001).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.047](10.7554/eLife.20600.047)

In addition, as with the pancreatic model, regulation of active α~5~β~1~-integrin by α~v~β~5~-integrin was needed for naïve fibroblasts to undergo rD-ECM-induced myofibroblastic activation ([Figure 11---figure supplement 2](#fig11s2){ref-type="fig"} and [Table 5](#tbl5){ref-type="table"}). Accordingly, treatment of naïve r-fibroblasts seeded within rD-ECM in the presence of small molecule FAK inhibitor PF573,228 ([@bib85]), blocked acquisition of myofibroblastic traits ([Figure 11---figure supplement 3](#fig11s3){ref-type="fig"}). In naïve r-fibroblasts, concomitant FAK and α~5~β~1~-integrin inhibition with combined PF573,228 and mAb16 significantly increased rD-ECM-induced myofibroblastic activation compared to PF573,228 treatment alone. Again, effects similar to those observed in the PDAC system were seen: α~v~β~5~-integrin co-inhibition with FAK failed to rescue rD-ECM naïve-to-myofibroblastic conversion ([Figure 11---figure supplement 3](#fig11s3){ref-type="fig"}). Also, pFAK-Y^397^ levels measured in 3D-adhesions of naïve r-fibroblasts induced by rD-ECM were effectively reduced in the presence of α~V~β~5~-integrin inhibitor (ALULA \[[@bib88]\]), rendering pFAK-Y^397^ levels similar to N-ECM levels ([Figure 11---figure supplement 4](#fig11s4){ref-type="fig"}). Culturing naïve r-fibroblasts in rD-ECM triggered lengthening of 3D-adhesion structures compared to those in rN-ECM, and this was effectively prevented by stabilization of α~5~β~1~-integrin activity using SNAKA51 ([@bib15]) ([Figure 11---figure supplement 5](#fig11s5){ref-type="fig"}). Last, plating naïve r-fibroblasts in rD-ECM increased levels of active α~5~β~1~-integrin that was localized away from 3D-adhesion structures compared to those in rN-ECM. These levels were regulated by α~v~β~5~-integrin, as treatment with ALULA restricted the enrichment of α~5~β~1~-integrin activity in areas lacking adhesions ([Figure 11---figure supplement 6](#fig11s6){ref-type="fig"}).10.7554/eLife.20600.048Table 5.αSMA stress fiber localization and expression levels in naïve renal fibroblasts cultured overnight within assorted renal ECMs.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.048](10.7554/eLife.20600.048)**rN-ECMrD-ECMrD+TGFβirD+DMSOTGFβiDMSOαvβ5-iα5β1-i5+α5-iα5β1-actIgGαSMA stress fiber localization**25% percentile0.050.880.280.6890.870.910.460.540.630.740.96**Median0.291.000.720.891.031.050.670.891.000.931.06**75% percentile0.671.100.971.031.171.160.961.061.331.542.19[^32][^33][^34][^35][^36][^37][^38][^39][^40][^41][^42][^43][^44][^45][^46][^47][^48]

Together, these results imply that the mechanisms identified for PDAC D-ECM production and activity were also relevant in RCC-associated fibroblastic stroma.

*In vivo* stromal activity and distribution of SMAD2/3, α~5~β~1~-integrin, and FAK predict patient survival and neoplastic recurrence {#s2-7}
-------------------------------------------------------------------------------------------------------------------------------------

Reciprocal signaling between tumor and stromal cells occurs *in vivo* ([@bib89]). Such bidirectional signaling is not simulated in the *in vitro* stroma 3D model used for the analysis described above. To extend our findings, we assessed whether the results we established *in vitro* were reflected *in vivo* in the original surgical samples used to harvest fibroblasts. We investigated whether the integrin redistribution phenotype that was commonly observed in both naïve fibroblasts in response to D-ECM and CAFs during D-ECM production *in vitro*, was also evident in the *in vivo* tumor-associated stroma. First, optimizing conditions *in vitro*, we used a simultaneous multi-channel immunofluorescence (SMI) approach, coupled with SMIA-CUKIE, to perform quantitative parallel analysis of seven relevant biomarkers in CAFs or control normal pancreatic stellate cells at the endpoint of production of D-ECM or N-ECM, respectively. These included a master mix (see Materials and methods) of epithelial and tumor cell markers (cyan; note, absent from *in vitro* specimens), the stromal marker vimentin (magenta), a nucleus-detecting DNA intercalating agent (Draq5, yellow), a 3D-adhesion marker (mAb11 \[[@bib18]\], red) and SNAKA51 ([@bib15]) to detect levels and localizations of active α~5~β~1~-integrin (green), anti-pFAK-Y^397^ (orange) and anti-pSMAD2/3 (indicative of TGFβ pathway activation \[[@bib90]\]; blue).

This method reiterated our observation that during D-ECM production *in vitro*, CAFs maintain high levels of active α~5~β~1~-integrin, with much of the active pool not localized to 3D-adhesions, as well as high levels of pFAK-Y^397^ that are localized at 3D-adhesions. TGFβ activation also increased during the production of D-ECM, represented by augmented total and nuclear pSMAD2/3 levels, when compared to naïve/normal cultures in which active α~5~β~1~-integrin mostly localizes at 3D-adhesion sites during N-ECM matrix production ([Figure 12](#fig12){ref-type="fig"}). We also conducted a parallel experiment using a classic indirect immunofluorescence approach to include a two-by-two marker comparison between active α~5~β~1~-integrin and 3D-adhesions, pFAK or pSMAD2/3. This experiment assessed the precision of the SMI approach, and evaluated the extent of phenotypic similarities between the pancreatic and renal matrix-producing CAFs and normal fibroblastic systems *in vitro*. While normal pancreatic and renal 3D cultures included active α~5~β~1~-integrin that is mostly localized at 3D-adhesion locations and included relatively low pFAK and pSMAD2/3 levels, PDAC and RCC CAF 3D matrix-producing cultures again exhibited high active α~5~β~1~-integrin levels that were evident at locations away from 3D-adhesions, concomitant with increased pFAK-Y^397^, and nuclei that were enriched with pSMAD2/3 ([Figure 12---figure supplement 1](#fig12s1){ref-type="fig"}).10.7554/eLife.20600.049Figure 12.*In vitro* characterization of normal and tumor-associated 3D matrix-producing fibroblastic cultures provide a set of prognostic markers to be tested *in vivo*.(**A**) SMI approach image outputs of *in vitro* 3D cultures of naïve fibroblastic stellate cells (normal) and desmoplastic CAFs (tumor associated) during ECM production. Leftmost panels demonstrate the positive staining of vimentin (magenta), and the lack of cytokeratin (cyan), indicating the purity of the fibroblasts isolated; nuclei are marked in yellow. White masks (SMI approach; SMIA) in the next panel represent vimentin-positive/cytokeratin-negative (in this case vimentin-positive only as there is no cytokeratin present) areas as recognized by the software following threshold values provided by the user. Next panels represent the assorted markers localized at pixels corresponding to SMI-selected masks and conforming to: active α~5~β~1~-integrin (S-α~5~β~1~ act.; in green), 3D-adhesions (S-3D-adh.; in red), pFAK-Y^397^ (S-pFAK; in orange), and pSMAD2/3 (S-pSMAD; in blue). (**B**) Graphs summarizing SMIA-CUKIE-generated data outputs representing median intensity levels of active α~5~β~1~-integrin (green bullets), pFAK-Y^397^ (orange bullets) and pSMAD2/3 (blue bullets) from data conditions as in (**A**) (\*\*\*p=0.0002). (**C**) Graphs summarizing SMIA-CUKIE-generated data from marker intersections indicating mean intensity levels of α~5~β~1~-integrin activity localized away from 3D-adhesions (green bullets) (\*\*\*p=0.0008), pFAK-Y^397^ at 3D-adhesions (orange bullets) (\*\*\*p=0.0002), and nuclear pSMAD~2/3~ (blue bullets) (\*\*\*p=0.0002).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.049](10.7554/eLife.20600.049)10.7554/eLife.20600.050Figure 12---figure supplement 1.*In vitro* characterization of pancreatic and renal normal and CAF unextracted 3D fibroblastic cultures.Samples correspond to normal fibroblastic stellate cells (**A**) and CAFs (**B**): depicted are spinning disc confocal-acquired images of indirect immunofluorescence of the assorted stromal markers. Images are shown as overlays to indicate the distribution of active α~5~β~1~-integrin (α~5~β~1~ act.; green) with regards to 3D-adhesion locations (3D-adh.; red), pFAK-Y^397^ (pFAK; orange), pSMAD2/3 (pSMAD; blue) and nucleus (yellow). Inserts correspond to monochromatic images of the corresponding marker.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.050](10.7554/eLife.20600.050)10.7554/eLife.20600.051Figure 12---figure supplement 2.*In vitro* uncovered traits correspond to *in vivo* PDAC and RCC stromal phenotypes.A seven-color simultaneous multi-channel immunofluorescent (SMI; see Materials and methods) approach was implemented to analyze FFPE tissue from the original patient surgical samples from which the fibroblasts used *in vitro* were harvested. (**A**) Normal tissue panel, representative images of PDAC and RCC FFPE samples. Note that the PDAC images correspond to pathological and matched normal samples from patient \#1; fibroblasts harvested from this pair of samples were immortalized and used to generate all human KOs that were presented above. (**B**) Tumor-associated tissue panel, representative images. The first column of images in (**A**) and (**B**) are overlaid images including the three colors used for 'masked' locations (see Materials and methods for details); epithelial/tumoral areas are pseudocolored in cyan, stromal vimentin is magenta, and nuclei labeled using draq5 are shown in yellow. The SMIA-CUKIE software (<https://github.com/cukie/SMIA_CUKIE>) was instructed to render an intersection 'mask' image (SMIA-mask 'S'; white) corresponding to pixel areas selected as stroma-positive and epithelial/tumoral-negative to exclude potential mesenchymal to epithelial transduced tumoral locations. Next, to the right of the SMIA mask image, are images of the corresponding markers showing only pixels corresponding to *bona fide* stromal 'masks' depicted in the mask image. Markers shown correspond to: active α~5~β~1~-integrin (S- α~5~β~1~ act.; green) and 3D-adhesions (S-3D-adh.; insert red), followed next to the right by pFAK-Y^397^ (S-pFAK; orange) and pSMAD2/3 (S-pSMAD; blue). Note that only pixels shown, which corresponded to the selected SMIA-mask (white), were quantitatively analyzed by the SMIA-CUKIE software (see [Figure 12---figure supplement 3](#fig12s3){ref-type="fig"} for values).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.051](10.7554/eLife.20600.051)10.7554/eLife.20600.052Figure 12---figure supplement 3.Quantification of *in vivo* SMI approach validates *in vitro* findings.(**A**) Individual patient SMIA-CUKIE-generated intensity values from PDAC and RCC normal or tumor-associated tissue samples, representing stromal levels of active α~5~β~1~-integrin (green bullets), pFAK-Y^397^ (orange bullets) and pSMAD2/3 (blue bullets). (**B**) Stromal active α~5~β~1~-integrin away from 3D-adhesions in pancreatic (left) and renal (right) normal or tumor associated tissues. Significance asterisks represent the following: (**A**) PDAC \*\*\*p=0.0013, \*\*p=0.0371; RCC \*\*\*\*p\<0.0001, \*\*\*p=0.0031; (**B**), \*\*p=0.0371 and \*\*\*\*p\<0.0001.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.052](10.7554/eLife.20600.052)

Having validated the seven-color SMI approach *in vitro*, we used the same technique, combined with SMIA-CUKIE analyses, on formalin-fixed paraffin embedded (FFPE) samples matching the original tissues from the five PDAC and four RCC patients used to generate the 3D stroma models analyzed *in vitro* ([Figure 12---figure supplement 2](#fig12s2){ref-type="fig"}). This analysis indicated clear increases in total α~5~β~1~-integrin activity, pFAK-Y^397^, and pSMAD2/3 in the stroma of PDAC and RCC compared to normal pancreatic and renal parenchyma ([Figure 12---figure supplement 3A](#fig12s3){ref-type="fig"}). When the same comparisons were performed for α~5~β~1~-integrin activity specifically localized away from stromal 3D-adhesion-positive pixels, the results again indicated clear increases ([Figure 12---figure supplement 3B](#fig12s3){ref-type="fig"}).

To determine whether this signature of CAF activation had prognostic value, we analyzed 128 PDAC and 126 RCC surgical specimens, using tissue microarrays (TMAs; [Table 6](#tbl6){ref-type="table"}). To establish baseline factors that are prognostic for survival, we initially evaluated the annotated clinical data for specimens on the TMAs (<https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx>) using univariate (Uni) and multivariate (MVA) analyses. For PDAC specimens, association between pathological N stage , overall pathological stage and positive nodes with overall survival (OS) indicated a significant increased risk of death correlated with increasing levels of these variables, with Uni hazard ratios (HRs) of 2.5 for pathological N (p=0.0002; 95% CI 1.5--4.2), 1.3 for pathological stage (p=0.01; 95% CI 1.1--1.6) and 1.15 for positive nodes (p=0.0001; 95% CI 1.1--1.2). Similar analyses looking at the association between clinical variables and recurrence-free survival (RFS) resulted in the identification of positive correlations for pathological N (HR = 2.1; p=0.009; 95% CI 1.2--3.7), pathological stage (HR = 1.4; p=0.01; 95% CI 1.0--2.0) and positive nodes (HR = 1.1; p=0.005; 95% CI 1.0--1.2). Further, MVA analyses for OS in PDAC specimens showed an association for N stage: HR = 1.9; p=0.06; 95% CI 1.0--3.6.10.7554/eLife.20600.053Table 6.PDAC and RCC cohorts included in TMAs.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.053](10.7554/eLife.20600.053)**PDACRCCSamplesNumberSamplesNumber**Tumor128 (128 OS and 102 DSS)Tumor126 (116 OS and 115 DSS)**Gendercases (%)Gendercases (%)**Female76 (59.40)Female34 (27)Male52 (40.60)Male90 (71.4)N/A0 (1.34)N/A2 (1.6)**Average age** years (range)**Average age** years (range)67.51 (37--91)60.67 (23--82)**TNM stageTNM stageNcases (%)Ncases (%)**033 (25.80)099 (78.57)191 (71.10)12 (1.59)20 (0)28 (6.35)30 (0)30 (0)N/A4 (3.10)N/A17 (13.49)**Tcases (%)Tcases (%)**00 (0)00 (0)110 (7.81)138 (30.16)234 (26.56)233 (26.19)366 (51.56)344 (34.92)413 (10.15)40 (0)N/A5 (3.91)N/A11 (8.73)**Mcases (%)Mcases (%)**0109 (85.16)085 (67.46)16 (4.70)134 (26.98)N/A13 (10.15)N/A7 (5.56)**Overall stagecases (%)Overall stagecases (%)**I17 (13.28)I32 (25.4)II38 (29.69)II26 (20.63)III53 (41.41)III25 (19.84)IV14 (10.94)IV35 (27.8)N/A6 (4.69)N/A8 (6.35)[^49]

We then asked whether the levels and localization of the stromal biomarker signature developed here yielded clinically useful prognostic biomarkers for PDAC, testing the idea that stromal pSMAD2/3, indicative of TGFβ signaling, would be associated with poor outcomes and active α~5~β~1~-integrin at 3D adhesions would be associated with better survival. For this, we conducted high-throughput SMI image acquisition and SMIA-CUKIE analysis of TMA PDAC samples, using univariate CART methodology to integrate the reporting levels of numerical outputs and intersections of the seven biomarkers of interest with OS or RFS. We observed significantly shorter OS in tumor surgical samples that had high stromal pSMAD2/3 values, whether values were quantified as mean or median stromal pSMAD2/3 intensity levels ([Figure 13](#fig13){ref-type="fig"}). Even though many patients did not show clinical improvement following surgery (so that our cohort presented a bias towards fast recurrence), high stromal pSMAD2/3 levels also correlated with shorter RFS ([Figure 13---figure supplement 1](#fig13s1){ref-type="fig"}). In addition, higher mean quantified levels of stromal α~5~β~1~-integrin activity also correlated significantly with longer RFS ([Figure 13---figure supplement 2A](#fig13s2){ref-type="fig"}). Interestingly, longer times to recurrence following surgery, quantified as the percentage area coverage relative to stromal occupied areas or as integrated intensities, were significantly associated with increased levels of integrin activity localized to stromal 3D-adhesion positive locations ([Figure 13---figure supplement 2B](#fig13s2){ref-type="fig"}). These results suggest that stromal activation of TGFβ, represented by high stromal pSMAD2/3 levels and indicative of capacity for active production of D-ECM production, is a prognostic stromal trait for poor outcome, while increased stromal levels of active α~5~β~1~-integrin at 3D adhesion positive areas may constitute a patient-protective PDAC-associated desmoplastic phenotype.10.7554/eLife.20600.054Figure 13.Stromal pSMAD2/3 levels are predictive of poor overall survival in PDAC patients.(**A**) CART-generated survival curves depicting overall survival (OS) as a function of stromal pSMAD2/3 expression in PDAC patients. Left and right curves were obtained using mean and median intensity levels, generated by SMIA-CUKIE, of stromal pSMAD2/3 related to OS, respectively. (**B**) Survival curves depicting pathological N, stage, and node status with PDAC patient OS. Colored tick-lines crossing Y axes indicate 0.5 survival marks and correspond to X axes locations that mark the median survival times obtained from the assorted curves. P values are shown. All patient data as well as SMIA-CUKIE generated data corresponding to human cohort constructed TMAs (shown in [Table 6](#tbl6){ref-type="table"}) can be found in the online table at the following publically available link: <https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx>. Note that since our cohorts comprised of samples obtained from surgeries, early neoplastic stages were overrepresented.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.054](10.7554/eLife.20600.054)10.7554/eLife.20600.055Figure 13---figure supplement 1.Stromal pSMAD2/3 levels are predictive of short recurrence-free survival in PDAC patients.(**A**) CART-generated survival curves indicative of recurrence-free survival (RFS) as a function of stromal pSMAD2/3 expression in PDAC patients. Left and right curves were obtained using mean and median intensity levels, generated by SMIA-CUKIE, of stromal pSMAD2/3 related to RFS, respectively. (**B**) Survival curves depicting pathological N, stage, and node status plotted against PDAC patient RFS fraction. Colored tick-lines crossing Y axes indicate 0.5 survival marks and correspond to X axis locations that mark the median RFS times obtained from the assorted curves. P values are shown. All patient data as well as SMIA-CUKIE generated data corresponding to human cohort constructed TMAs (shown in [Table 6](#tbl6){ref-type="table"}) can be found in the online table at the following publically available link: <https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx>. Note that since our cohorts comprised of samples obtained from surgeries, early neoplastic stages were overrepresented.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.055](10.7554/eLife.20600.055)10.7554/eLife.20600.056Figure 13---figure supplement 2.Stromal active α~5~β~1~-integrin levels localized at 3D-adhesions correlate with longer recurrence-free survival in PDAC patients.CART-generated survival curves depicting recurrence-free survival (RFS) as a function of active stromal α~5~β~1~-integrin levels in PDAC patients. Curves were obtained using (**A**) active α~5~β~1~-integrin median intensity levels and (**B**) percentage area coverage or integrated intensity of stroma populated by active α~5~β~1~-integrin localized at 3D-adhesions that were generated by SMIA-CUKIE, related to RFS. Colored tick-lines crossing Y axes indicate 0.5 survival marks and correspond to X axis locations that mark the median RFS obtained from the curves. P values are shown. All patient data as well as SMIA-CUKIE-generated data corresponding to human cohort constructed TMAs (shown in [Table 6](#tbl6){ref-type="table"}) can be found in the online table at the following publically available link : <https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx>. Note that since our cohorts comprised of samples obtained from surgeries, early neoplastic stages were overrepresented.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.056](10.7554/eLife.20600.056)10.7554/eLife.20600.057Figure 13---figure supplement 3.Stromal levels and locations of p-SMAD2/3, active α~5~β~1~-integrin, and pFAK correlate with short overall survival in RCC patients.(**A--C**) CART-generated survival curves depicting overall survival (OS) as a function of stromal assorted marker levels in RCC patients. (**A**) Left and middle curves correspond to mean and total intensity levels of stromal pSMAD2/3 and right curves to pSMAD2/3 mean intensity levels particularly localized at stromal nuclei, as a function of OS. (**B**) OS curves as a function of stromal active α~5~β~1~-integrin levels. Top left curves show mean intensity of active α~5~β~1~-integrin related to OS, top middle curves show mean intensity of active α~5~β~1~-integrin at 3D adhesions related to OS, and top right curves show the percentage area coverage of active α~5~β~1~-integrin at 3D adhesions related to OS. Bottom left curves depict median intensity levels of active α~5~β~1~-integrin away from 3D adhesions, while bottom right curves depict percentage area coverage of active α~5~β~1~-integrin away from 3D adhesions. (**C**) Curves depicting OS as a function of stromal pFAK. Top left curves show mean intensity of pFAK related to OS, top middle curves show percentage area coverage of pFAK related to OS, and top right curves show the total intensity pFAK related to OS. Bottom left curves depict median intensity levels of pFAK at 3D adhesions, bottom middle curves depict percentage area coverage of pFAK at 3D adhesions, and bottom right curves depict total intensity of pFAK at 3D adhesions. Colored tick-lines crossing Y axes indicate 0.5 survival marks and correspond to X axis locations that mark the median survival times obtained from the assorted curves. P values are shown. All patient data as well as SMIA-CUKIE-generated data corresponding to human cohort constructed TMAs (shown in [Table 6](#tbl6){ref-type="table"}) can be found in the online table at the following publically available link: <https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx>. Since our cohorts were comprised of samples obtained from surgeries, early neoplastic stages were overrepresented. Note that the above-mentioned links host RCC clinical data that provided the following results, which were obtained prior to CART analyses to assure that in spite of the bias provided by the use of surgical samples, the cohort in question showed significant associations between clinical and outcome variables and OS and Disease-Specific Survival (DSS): associations between pathological stage and OS had HRs of 2.4 (Uni; p=1.11E-10; 95% CI 1.9--3.2) and 3.2 (MVA; p=0.001; 95% CI 1.6--6.2), respectively. Also, Uni analyses of pathological T, N and M showed significant correlation with OS (T ---HR = 2.0, p=4.16E-05, 95% CI 1.4--2.8; N --- HR = 2.1, p=0.0003, 95% CI 1.4--3.1; and M --- HR = 5.4, p=3.79E-10, 95% CI 3.2--9.1). Similarly, Uni and MVA analyses suggested that shorter DSS times are associated with advanced pathological stage (Uni ---HR = 3.1, p=7.94E-11 and 95% CI 2.2--4.3; MVA --- HR = 3.4, p\<0.0001% and 95% CI 1.6--7.3).**DOI:** [http://dx.doi.org/10.7554/eLife.20600.057](10.7554/eLife.20600.057)10.7554/eLife.20600.058Figure 13---figure supplement 4.Stromal levels and locations of p-SMAD2/3, active α~5~β~1~-integrin, and pFAK correlate with short disease specific survival in RCC patients.(**A**-**C**) CART-generated survival curves depicting disease specific survival (DSS) as a function of stromal assorted marker levels in RCC patients. (**A**) Left and right curves correspond to mean stromal-and stromal-nuclei- localized intensity levels of pSMAD, related to DSS. (**B**) DSS curves as a function of stromal active α~5~β~1~-integrin levels. Top left curves show mean intensity of active α~5~β~1~-integrin related to DSS, top middle curves show stromal percentage active α~5~β~1~-integrin related to DSS, and top right curves show the total stromal intensity levels of active α~5~β~1~-integrin related to DSS. Middle left, middle and right curves depict mean, percentage coverage and total intensity levels of active stromal α~5~β~1~-integrin at 3D adhesions, respectively, each related to DSS. Bottom row from left to right corresponds to mean, median, percentage coverage and total intensity levels of active stromal α~5~β~1~-integrin away from 3D adhesions, each related to DSS. (**C**) Survival curves depicting DSS as a function of stromal pFAK. Top from left to right: curves showing median, percentage coverage and total intensity levels of stromal pFAK related to DSS. Bottom from left to right: curves showing mean, median, percentage coverage and total intensity of stromal pFAK localized at 3D-adhesions related to DSS. Colored tick-lines crossing Y axes indicate 0.5 survival marks and correspond to X axis locations that mark the median survival times obtained from the assorted curves. P values are shown. All patient data as well as SMIA-CUKIE-generated data corresponding to human cohort constructed TMAs (shown in [Table 6](#tbl6){ref-type="table"}) can be found in the online table at the following publically available link: <https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx>. Note that since our cohorts comprised of samples obtained from surgeries, early neoplastic stages were overrepresented.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.058](10.7554/eLife.20600.058)

To investigate whether these patterns are also seen in stroma associated with an additional epithelial cancer, we analyzed the RCC cohort ([Table 6](#tbl6){ref-type="table"}). Initial Uni and MVA analyses on the clinical data tested whether, in spite of the bias generated by the retrospective use of surgical cases, the cohort in question showed significant associations between pathological stages and OS and Disease-Specific Survival (DSS). Importantly, using CART analyses, we determined that RCC patients with high stromal levels of pFAK-Y^397^ localized at 3D-adhesions, higher nuclear pSMAD2/3, or increased levels of active α~5~β~1~-integrin, measured as mean, median or total stromal intensity levels as well as stromal percentage area coverages, had significantly shorter OS and DSS ([Figure 13---figure supplements 3](#fig13s3){ref-type="fig"} and [4](#fig13s4){ref-type="fig"}).

Together, these results strongly support the idea that the markers of an active desmoplastic phenotype, as defined herein, are useful in predicting patient outcomes.

Discussion {#s3}
==========

Understanding the activity of and clinically exploiting tumor-associated stroma have for a long time posed challenges, given strong evidence for both tumor-limiting and tumor-promoting stromal functionality ([@bib62]; [@bib10]; [@bib54]; [@bib69]; [@bib23]). The data in this study are useful by providing insight into stromal function in several ways. First, by addressing prior studies that suggest that changes in tumor-associated ECM are necessary for TGFβ-dependent myofibroblastic activation ([@bib20]; [@bib82]), they dissect the interaction of TGFβ with N-ECM versus D-ECM. These results indicate that TGFβ contributes to N-ECM assembly, and that it is essential solely for the phenotypic remodeling required for conversion to anisotropic D-ECM, but not for secretion of ECM components per se in the context of D-ECM production. This fact is supported by the observation that CAFs require TGFβ signaling for the myofibroblastic production of anisotropic D-ECM and for expression of αSMA, while the myofibroblastic features that are acquired by normal/naïve fibroblasts in response to D-ECM do not entail this signaling pathway. Second, our work addressed two cell-ECM receptor integrin heterodimers that have previously been shown to influence myofibroblastic activation, α~v~β~5~ and α~5~β~1~ ([@bib6]; [@bib58]; [@bib22]). Our study shows that both of these integrin heterodimers are abundant on the surface of both naïve fibroblasts and CAFs, but have distinct roles in the ability of naïve fibroblasts to respond to and of CAFs to assemble anisotropic D-ECM. In particular, our work integrated multiple approaches to emphasize an important role for α~v~β~5~-integrin in the response of naïve fibroblasts to D-ECM and for CAFs in producing anisotropic matrix. We also found that while α~5~β~1~ counteracted the response of naïve fibroblasts to D-ECM, it was, not surprisingly, essential for matrix fibrillogenesis. Interestingly, in the context of extracted D-ECM imparting naïve-to-myofibroblastic activation, cross-signaling between the two integrins was apparent, with α~v~β~5~ regulating the internalization of part of the elevated pool of activated α~5~β~1~ to intracellular endosomal compartments ([Figure 14](#fig14){ref-type="fig"}). Third, we also defined specific ECM responses as independent of, or dependent on, the canonical integrin effector FAK. Fourth, importantly, we demonstrated that the signaling relationships identified in this study were valid in multiple model systems, including human primary PDAC and RCC, as well as additional murine models. Fifth, we used high-content imaging and data analysis to demonstrate that interactions analyzed *in vitro* can be used to define an *in vivo* stromal signature that has prognostic value, addressing a significant clinical goal.10.7554/eLife.20600.059Figure 14.Model depicting D-ECM-induced α~V~β~5~ regulation of active α~5~β~1~-integrin localization during naïve-to-myofibroblastic activation.Essentially, naïve fibroblasts grown in N-ECMs do not trigger a surplus in active α~V~β~5~ and α~5~β~1~-integrin conformations. Consequently, the non-pathological N-ECM spares regulation of α~V~β~5~-integrin activity and assures physiological accumulation of low active α~5~β~1~-integrin levels at the PM, rendering fibroblasts inactive. D-ECMs induce an excess of active α~5~β~1~-integrin and regulate α~V~β~5~-integrin-mediated relocation of active α~5~β~1~-integrin from the PM to intracellular (e.g., late endosomal) pools, resulting in myofibroblastic activation. Last, this D-ECM activity is dependent on the activity of α~V~β~5~-integrin, as inhibition of α~V~β~5~-integrin maintains active α~5~β~1~-integrin at the PM (similarly to N-ECM regulation of active α~5~β~1~-integrin locations), which averts D-ECM-induced myofibroblastic activation. The summarized data provide a possible explanation for the early model presented in [Figure 3G](#fig3){ref-type="fig"}, which called for a D-ECM control of α~v~β~5~ regulation of active α~5~β~1~ and suggests that the alluded to regulation constitutes a re-localization of active α~5~β~1~ to intracellular endosomal compartments, allowing D-ECM-induced naïve-to-myofibroblastic activation.**DOI:** [http://dx.doi.org/10.7554/eLife.20600.059](10.7554/eLife.20600.059)

There is strong evidence for desmoplastic stromal reciprocation, involving altered ECM (e.g., D-ECM) and adjacent tumor and/or stromal cells during PDAC development and progression ([@bib99]; [@bib89]; [@bib3]; [@bib32]; [@bib77]). Several prior studies have searched for proteomic signatures of normal vs. tumor-affected stroma ([@bib93]), in order to identify stromal traits that are associated with favorable or unfavorable clinical outcomes ([@bib25]; [@bib64]). Some of these signatures have been proposed to serve as clinically relevant tumor sub-type indicators ([@bib14]). The desmoplastic 3D models used in this study allowed us to functionally dissect both mechanisms of D-ECM production by CAFs, including the specific induction of anisotropic ECMs, and D-ECM-induced responses such as myofibroblastic activation of naïve fibroblasts, mechanistically informing the significance of such signatures.

A role for TGFβ in regulating the production of anisotropic ECM had been previously suggested ([@bib47]). Remodeling that causes isotropic ECMs to become increasingly anisotropic, together with increases in matrix tension and stiffness, are all features of chronic fibrosis that physically enhance the accessibility and activation of TGFβ by myofibroblastic integrins ([@bib49]). Another interesting study demonstrated that substrate stiffness influences the ability of a cell induced *in vitro* to undergo myofibroblastic activation, and can positively or negatively influence the degree to which a cell is able to accurately acquire the characteristics ([@bib1]) of a CAF* in vivo*. In accord with this line of thinking, one may argue that specific ECM topographies, and in particular the overall physical properties of cell substrates, play key pathophysiological roles in promoting positive feedback loops involving myofibroblastic cells and D-ECMs in fibrous tumor-associated microenvironments, such as PDAC-associated desmoplasia ([@bib3]). Our results indicated that while TGFβ is necessary for normal fibroblasts to assemble N-ECM, it is essential solely for the phenotypic remodeling of anisotropic D-ECM by CAFs, and not for its production. Negating CAF capability to produce anisotropic D-ECM restricts tumor growth *in vivo* ([@bib35]), while increased levels of anisotropic D-ECM correlate with poor patient survival and cancer relapse ([@bib33]; [@bib16]; [@bib11]). Inhibition of the TGFβ type I receptor, which reduces the activity of a downstream canonical effector of TGFβ, SMAD2/3, is known to hinder matrix fibrillogenesis ([@bib12]). In our work, elevated fibroblast-expressed pSMAD2/3 and nuclear translocation of this protein in CAFs producing D-ECM correlated with short time to recurrence and reduced survival in both PDAC and RCC patient cohorts. Results from our study also suggest that while TGFβ-targeted therapeutic interventions may revert D-ECMs to their naturally tumor-suppressive isotropic phenotype, the same approach could ablate homeostatic N-ECM. Consideration of this possibility is important because total ablation of TGFβ induces multifocal inflammatory disease ([@bib84]) and because clinical trials are currently assessing TGFβ-inhibitory drugs ([@bib38]).

While the understudied α~v~β~1~ heterodimer was recently recognized as a regulator of latent TGFβ in fibrosis ([@bib74]), α~v~β~5~ and α~5~β~1~ integrins are involved in myofibroblastic activation ([@bib6]; [@bib58]; [@bib22]). Both α~v~β~5~ and α~5~β~1~ integrin receptors were abundant in primary fibroblasts collected from patients. Our results demonstrated that in response to D-ECM, α~v~β~5~-integrin activity supports the relocalization of active α~5~β~1~-integrin to intracellular endosomal pools and that this vesicular accumulation is needed for the maintenance of naïve-to-myofibroblastic activation. In addition, genetic loss (but not transient inhibition) of α~5~β~1~, which resulted in slow-growing naïve cells, altogether prevented *de novo* D-ECM induction of naïve-to-myofibroblastic transition. Interestingly, in other studies, α~5~β~1-~positive elongated 'super mature' adhesion structures ([@bib22]; [@bib40]), which control tension-dependent recruitment and retention of αSMA at stress fibers, were found to play a functional role in myofibroblastic activation ([@bib34]). Together with our findings, these data suggest that α~5~β~1~ participates in the regulation of αSMA expression, whereas the α~v~β~5-~regulated relocation of activated α~5~β~1~-integrin participates in αSMA localization to stress fibers. Other studies have shown that inhibition of α~v~β~5~-integrin activates β~1~-integrin, counteracting ECM-dependent myofibroblastic αSMA stress fiber localization ([@bib92]). However, the nature of the specific β~1~-integrin heterodimer and the mechanistic details of this negative myofibroblastic regulation were previously unknown. We further defined the α~5~β~1~ activity that regulates αSMA localization as independent of FAK. Interestingly, a previously defined α~5~β~1~ integrin activity needed to form 3D-adhesions in both normal cell-derived ECMs and *in vivo* is also FAK-independent ([@bib18]).

Intriguingly, our results indicate that D-ECM induces α~v~β~5~-integrin-dependent redistribution of active α~5~β~1~-integrin to intracellular pools, within structures that include CD81-positive multivesicular ([@bib26]) and late Rab7/Rab11 endosomes. We found that using SNAKA51 to stabilize α~5~β~1~-integrin activity resulted in reduced internalization, a finding that differs from results reported previously which indicated that treating cells with SNAKA51 internalized active integrin ([@bib59]). It is possible that these differences reflect differences in analytic time points. [@bib59]) looked at a time point of 20 min after treatment, whereas we analyzed data after overnight incubation with SNAKA51, which may have led to compensatory enrichment of activity at the PM in our study, and thus further investigation is required. However, it is interesting that engagement of the integrin-binding ligands RGD, osteopontin and cilengitide with α~v~β~3~ and α~5~β~1~ results in the association of α~5~β~1~ with a Rab-coupling protein which regulates its localization concomitant with EGFR ([@bib13]). It is therefore possible that the use of ALULA ([@bib15]) in this study triggered activation of the Rab cellular trafficking machinery, in a manner restricted by α~v~β~5~ activity during tumor-associated desmoplasia.

The importance of identifying reliable biomarkers for early PDAC diagnostics ([@bib52]) and improved RCC prognostic predictions is clear. Recently, increased stromal density was deemed to be a better prognostic outcome in a retrospective study looking at pancreatic cancer patients who underwent pancreaticoduodenectomy followed by adjuvant treatment, while assessing overall levels of stromal αSMA was found to be inconclusive ([@bib7]). In the future, it will be interesting to test whether the increased stromal density, perhaps in the context of specific relocalization of αSMA, corresponds to this study's 'patient-protective' phenotype. This example, together with additional studies that suggest both tumor-protective and -detrimental roles for highly heterogeneous desmoplasia ([@bib68]; [@bib76]; [@bib83]; [@bib7]; [@bib19]; [@bib81]), underscore the need for better stromal categorization. The new software developed in this study to facilitate analysis of the discrete localizations of the various markers specifically in stroma (freely downloadable from <https://github.com/cukie/SMIA_CUKIE>) allows analysis of batch-sorted monochromatic images in bulk, and generation of qualitative and quantitative outputs to evaluate biomarkers located at any given mask and/or marker intersection. In this study, we used this software to identify predictive biomarker signatures for PDAC and RCC patients. Stromal increases in pSMAD2/3 and pFAK correlated with worse outcomes but, in spite of the bias introduced by the use of resectable surgical cases, we identified a patient-protective stroma phenotype in PDAC, in which increased active α~5~β~1~-integrin selectively localized at stromal 3D-adhesions is associated with improved outcomes. By contrast, intensities of active α~5~β~1~-integrin activity correlated with increasingly unfavorable OS as well as DSS in RCC patients. Hence, locations and intensities of stromal α~5~β~1~-integrin activity concomitant with constitutive active pFAK-Y^397^ could represent novel desmoplasia-dependent outcome-predicting stromal patterns. As our *in vitro* studies suggested a complex function for α~5~β~1~-integrin activity, and given the differences between the molecular characteristics of distinct tumor subtypes, we emphasize that individual tumor classes will require careful study before these biomarkers could be used as predictive clinical indicators.

In summary, our study provides new insights into the intracellular and extracellular signaling processes that support desmoplastic formation, with mechanistic studies facilitated by the use of *in vitro* fibroblast-derived 3D ECMs. Specifically, the results suggest that α~v~β~5~-integrin prevents FAK-independent α~5~β~1~-integrin activity from impairing D-ECM-induced naïve-to-myofibroblastic activation by relocating this activity to multivesicular and other late endosomes. β~5~-integrin\'s contribution to the ability of CAFs to produce functional anisotropic D-ECM, in which active α~5~β~1~-integrin levels are not altered, distinguishes between naïve-to-myofibroblastic activation and myofibroblastic CAFs. Importantly, this study supports the idea that stromal normalization, to produce a form that plays a tumor-suppressive role ([@bib62]; [@bib86]; [@bib99]; [@bib10]; [@bib3]) may be a favorable approach, especially as some recent attempts aimed at completely abolishing stroma have proven harmful to patients ([@bib8]; [@bib68]; [@bib76]). This work also suggests specific protein targets that may be useful for stroma-normalizing therapies. For example, these data suggest that future therapeutic strategies might involve combinatorial treatments to inhibit TGFβ and α~v~β~5~-integrin. Finally, the study also suggests that monitoring the level and localization of stromal pSMAD2/3, as well as those of α~5~β~1~-integrin activity together with those of stromal pFAK, could assist in stratifying individuals that would benefit from α~v~β~5~-integrin and other chronic fibrosis-directed therapeutics.

Materials and methods {#s4}
=====================

Ethics statement {#s4-1}
----------------

Human tissues were collected under exemption-approval of the Center's Institutional Review Board after patients signed a written informed consent agreeing to donate samples to research. To protect patients\' identities, samples were coded and distributed by the Institutional Biosample Repository Facility.

Reagents and cell lines {#s4-2}
-----------------------

All reagents (see below) were from Sigma-Aldrich (St. Louis, MO) unless listed otherwise. All primary and immortalized fibroblasts were cultured at 37°C under 5% CO~2~ using Dulbecco's Modified Eagle's Medium (Mediatech (Manassas, VA)) supplemented with 10% or 15% (murine or human cells, respectively) Premium-Select Fetal Bovine Serum (Atlanta Biologicals (Lawrenceville, GA)), 2 mM L-glutamine and 100 u/ml-μg/ml penicillin-streptomycin. Panc1, FAK^+/+^, FAK^−/−^, SYF, and littermate wild-type control cells were from the American Tissue Culture Collection (Manassas, VA). FAK-KD and hTert controls were a gift from David Schlaepfer (UCSF, San Francisco, CA).

A request to annotate the human fibroblastic cell lines that were generated in this study was issued to the Research Resource Identifiers for their quarterly year annotations. Also, these cells were submitted for CellCheckTM 16 Marker STR Profile and Inter-species Contamination Test for human cell line authentication to IDEXX Bioresearch (Columbia, MO). Markers evaluated to authenticate the diversity of cell origins (patients) were: AMEL, CSF1PO, D13S317, D16S539, D18S51, D21S11, D3S1358, D5S818, D7S820, D8S1179, FGA, Penta_D, Penta_E, TH01, TPOX, and vWA. Interspecies contamination testing included comparison of human samples versus mouse, rat, Chinese hamster and African green monkey DNA. Mycoplasma contamination status was negative. This study did not utilize cell lines listed in the Database of Cross-Contaminated or Misidentified Cell Lines (Version 7.2) from the International Cell Line Authentication Committee (ICLAC).

Isolation and characterization of fibroblastic cells {#s4-3}
----------------------------------------------------

Pan-keratin (AE1/AE3 -Dako (Carpinteria, CA)) negative and vimentin (EPR3776 -Abcam (Cambridge, MA)) positive fibroblastic cells were isolated from fresh surgical normal and tumoral tissue samples using the enzymatic tissue digestion approach as published ([@bib30]). Fresh surgical tissues from normal or tumoral pancreas and from kidney or murine skin (see below) were collected into conical tubes containing Dulbecco's phosphate-buffered saline with antibiotics at 4°C. Samples were minced and subjected to overnight gelatinase digestion. Digested tissues were subjected to 10 min 200 g centrifugation followed by three sequential size-exclusion filtrations using sterile nylon mesh strainers of pore sizes 500 μm, 100 μm and 40 μm. The resulting cells were characterized as naive or CAFs according to methods reported previously ([@bib36]; [@bib33]; [@bib4]). Cells were used for no longer than 12 passages while maintained within their own derived ECMs (if cells were not to be maintained in 3D ECMs, only 4--6 passages would have been used).

Fibroblasts used in the study were harvested from five different patients for PDAC (including two matched pairs) and four for RCC models, while the fibroblasts used for the murine model of skin squamous-cell-carcinoma-associated desmoplasia were from our published study in which the D-ECM-induced naïve-to-myofibroblastic transition was first described ([@bib4]). Note that PDAC fibroblastic cells from patient \#1 were used *in vitro* throughout the study unless stated otherwise.

Preparation of fibroblast-derived 3D ECMs {#s4-4}
-----------------------------------------

We obtained cell-derived ECMs using our published protocols ([@bib30]). Confluent fibroblastic cultures were maintained for 7 days in the presence of daily added and freshly prepared ascorbic acid at a concentration of 50 ìg/ml. The resulting 'unextracted' 8 day long multilayered 3D cultures were used as naïve or CAF-matrix---producing cultures in this study and were processed for phenotypic characterization and ECM alignment (isotropy vs. anisotropy assessments). Cell extraction, to obtain N- and D-ECMs, was achieved using 0.5% (v/v) Triton X-100 complemented with freshly added 20 mM NH~4~OH. Extracted N- and D-ECMs were stored sealed, using Parafilm, in culturing plates with Dulbecco's phosphate-buffered saline lacking CaCl~2~ and MgSO~4~ at 4°C. The resulting extracted matrices were used for D-ECM-induction of naïve-to-myofibroblastic activation. For the production of 3D matrices using inhibitors, the following were added during the 7 days of ECM production: TGFβ1R small molecule inhibitor (SB431542) (25 μM); DMSO; conformation-dependent anti-active α~5~-integrin functional antibody ([@bib15]) (45 μg/ml SNAKA51 \[a gift from Martin Humphries, Manchester University, UK\]); functional-blocking anti-α~v~β~5~-integrin ([@bib15]) (60 μg/ml ALULA \[a gift from Drs Dean Sheppard (UCSF, San Francisco, CA), and Shelia Violette (Biogen, Cambridge, MA\]); or species-matched non-immunized isotypic antibodies.

RT-qPCR {#s4-5}
-------

The Ambion PureLink kit (Life Technologies) was used, according to manufacturer's instructions, to extract total cellular RNA from the various experimental conditions and tested for RNA quality using a Bioanalyzer (Agilent). Contaminating genomic DNA was removed using Turbo DNA free from Ambion. RNA concentrations were determined with a spectrophotometer (NanoDrop; Thermo Fisher Scientific). RNA was reverse transcribed (RT) using Moloney murine leukemia virus reverse transcriptase (Ambion) and a mixture of anchored oligo-dT and random decamers (IDT). Two reverse-transcription reactions were performed for each experimental duplicate sample using 100 ng and 25 ng of input RNA. Taqman assays were used in combination with Taqman Universal Master Mix and run on a 7900 HT sequence detection system (Applied Biosystems). Cycling conditions were 95°C, 15 min, followed by 40 (two-step) cycles (95°C, 15 s; 60°C, 60 s). Ct (cycle threshold) values were converted to quantities (in arbitrary units) using a standard curve (four points, four-fold dilutions) established with a calibrator sample. Values were averaged per sample and standard deviations were from a minimum of two independent PCRs. Polymerase (RNA) II (DNA directed) polypeptide F (POLR2F) was used as internal control. Identification numbers of commercial assays (Life Technologies) and sequences of the primers and probe for the POLR2F assay are: Hs00363100_m1 (PALLD1), Hs00426835_g1 (ACTA2), TGCCATGAAGGAACTCAAGG (forward), TCATAGCTCCCATCTGGCAG (reverse), and 6fam-CCCCATCATCATTCGCCGTTACC-bqh1 (probe).

D-ECM prompted naïve-to-myofibroblastic activation {#s4-6}
--------------------------------------------------

Human naïve or assorted murine fibroblasts were pre-incubated for 45 min with functional antibodies, small molecule inhibitors or controls, prior to overnight culturing within assorted ECMs. Experiments were carried out in the presence or absence of 45 μg/ml SNAKA51 ([@bib15]), 60 μg/ml ALULA ([@bib88]), 250 μg/m mAb16 ([@bib2]) (a gift from Kenneth Yamada \[NIDCR/NIH, Bethesda, MD\]), BMA5 ([@bib28]) diluted as instructed by the manufacturer (Millipore, Temecula, CA), IgG control, DMSO, or small molecule inhibitor of FAK (PF573,228 \[[@bib85]\]). ECM-induced phenotypes were assessed by RT-qPCR, western blot or immunofluorescence as described in the corresponding Methods sections.

Array to detect constitutive plasma-membrane-localized levels of assorted β-integrin heterodimers {#s4-7}
-------------------------------------------------------------------------------------------------

An integrin-mediated cell adhesion assay was conducted to detect cell surface levels of heterodimeric integrin receptors on the assorted fibroblastic cells. The array, ECM531 from Millipore, is based on the use of selected monoclonal antibodies against assorted β-integrin heterodimers and testing amounts of cell adhesion to each particular antibody. Cells are incubated onto an array of wells coated with the various antibodies and then washed, before adherent cells are counted. The number of cells adhering to a specific antibody is directly related to the amount of the specific integrin receptor expressed at the cell surface. Numbers of adherent cells' surfaces are evaluated by 540--570 nm absorbance of cells stained using a staining reagent provided with the kit according to the manufacturer\'sinstructions.

TGFβ ELISA {#s4-8}
----------

Quantification of TGFβ stored/deposited into unextracted fibroblast 3D cultures was performed using the DuoSet human TGFβ1 ELISA kit, as instructed by the manufacturer (R and D Systems, \#DY240-05). All wash buffers and reagents were provided in the DuoSet Ancillary Reagent Kit 1 (R and D systems, \#DY007). Briefly, whole cell lysates (or conditioned media as controls) were obtained from fibroblasts and loaded onto plates that were pre-coated with capture antibody overnight at RT. After 2 hr incubation of lysates, concentrated media and calibration curve standards, wells were rinsed three times with wash buffer and then incubated for 2 hr at RT with detection antibody. Next, after three more washes, streptavidin-HRP was incubated in the wells for 20 min at RT. After another three washes, substrate solution was added to the wells, and after 15 min, stop solution was added to halt the HRP-substrate reaction. Next, OD at 450 nm and 570 nm was obtained using the Synergy H1 plate reader (BioTek). The OD at 570 nm was subtracted from the OD at 450 nm to correct for plate imperfections. Then the standard curve was constructed, and the concentration of TGFβ (pg/mL) in experimental samples was determined. Last, TGFβ concentration was normalized to the amount of protein loaded into each well and then normalized to control TAF levels, with the modal value referred to as one a.u. (arbitrary unit).

Electron microscopy {#s4-9}
-------------------

Au~8~-SNAKA51 and Au~15~-mAb11 gold-antibody complexes were conjugated as described in [@bib37]). Cells from functional assays were fixed with 2.0% paraformaldehyde in PBS, pH 7.4, at 4°C overnight. Following antibody incubation, cells were fixed with 2.0% glutaraldehyde washed and post-fixed in 2.0% osmium tetroxide for 1 hr at room temperature. Dehydration through a graded ethanol series and propylene oxide was followed by embedding samples in EMbed-812 (Electron Microscopy Sciences \[Hatfield, PA\]). Sections were stained with 2% alcoholic uranyl acetate and scanned with a FEI Tecnai electron microscope, while images were acquired using a Hamamatsu digital camera operated via AMT Advantage image capture software (AMT 542.544; 18 Sep 2009).

Indirect immunofluorescence (*in vitro*) {#s4-10}
----------------------------------------

The method for indirect immunofluorescence was as published previously ([@bib36]; [@bib4]; [@bib30]; [@bib18]), only Triton was omitted for non-permeable conditions. Samples were either fixed/permeated or solely fixed as published ([@bib30]). Following 60 min blocking, using Odyssey Blocking Buffer (LI-COR Biosciences, Lincoln, NE) containing 1% donkey serum, the following primary antibodies were incubated in combinations as indicated by the specific experiments for a period of 60 min: anti-pan-cytokeratin (clones: AE1/AE3) (AB_2631307) from Dako (Carpinteria, CA), rabbit monoclonal anti-Vimentin EPR3776 (AB_10004971) (1:200) from Abcam (Cambridge, MA), rabbit polyclonal anti-human fibronectin (AB_476961) (1∶200) and 1 A4 mouse anti-αSMA (AB_476701) (1∶300) were from Sigma-Aldrich (St. Louis, MO), mouse SNAKA51 Ab (45 μg/ml) was a gift from M Humphries ([@bib15]), rat mAb11 (45 μg/ml) from K Yamada ([@bib2]), rabbit polyclonal anti-palladin (AB_2158782) (1:200) (Proteintech, Chicago, IL), rabbit monoclonal anti-phospho FAK \[Y397\] (AB_2533701) (1:200) (Invitrogen, Camarillo, CA), rabbit monoclonal anti-phospho Smad2 \[S465/467\]/Smad3 \[S423/425\] (AB_2631089) (1:200) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-Rab5 (AB_10828212) (1:150) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-Rab7 (AB_10831367) (1:25) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-Rab11 (AB_10693925) (1:25) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-EEA1 (1:150) (AB_10828484) (Cell Signaling, Danvers, MA), rabbit monoclonal anti-CD81 (AB_2275892) (1:35) (Santa Cruz Biotechnologies, Dallas, Texas) and species-matched non-immunogenic mouse IgG (Abcam) and Rat IgG (Jackson ImmunoResearch Inc., West Grove, PA) were used at equal concentrations to their corresponding matching isotypes. Following three rinses of 5 min with PBS-Tween20 (0.05%), secondary antibodies were incubated for 60 min using donkey F(ab\')two fragments (1∶100) cross-linked to assorted fluorophores (Jackson ImmunoResearch Laboratories Inc.). When mentioned, SYBR Green (1∶10,000 Invitrogen \[Eugene, OR\]) or Draq-5 (1:10,000 Pierce Biotechnology \[Rockford, lL\]) and/or fluorescent Phalloidin (2.5 μl/100 μl, Invitrogen \[Eugene, OR\]) were included. Following washes with PBS and a final rinse with double-distilled water, samples were mounted using Prolong Gold anti-fading reagent from Life Technologies (Carlsbad, CA). When needed, anti-αSMA and/or SNAKA51 primary antibodies were pre-linked to fluorescent dye crystals using the Mix-n-Stain^TM^ kit following the manufacturer\'s recommendations (Biotium, Hayward, CA).

Confocal image acquisition {#s4-11}
--------------------------

Confocal spinning disk Ultraview (Perkin-Elmer Life Sciences, Boston, MA) images were acquired with a 60X (1.45 PlanApo TIRF) oil immersion objective, under identical exposure conditions per channel using Volocity 6.3.0 (SCR_002668) (Perkin-Elmer Life Sciences, Boston, MA). Maximum reconstruction projections were obtained using MetaMorph 7.8.1.0 (SCR_002368) (Molecular Devices, Downingtown, PA) as described previously ([@bib4]). For monochromatic *in vitro* image analyses using SMIA-CUKIE, please refer to SMI methods below.

ECM fiber orientation analysis {#s4-12}
------------------------------

Fibronectin channel monochromatic images were analyzed via ImageJ's (SCR_003070) OrientationJ plugin (SCR_014796) (<http://bigwww.epfl.ch/demo/orientation/>) as described previously ([@bib30]; [@bib75]). Numerical outputs were normalized by setting mode angles to 0˚, and correcting angle spreads to fluctuate between −90˚ and 90˚. Angle spreads for each experimental condition, corresponding to a minimum of three experimental repetitions and five image acquisitions per condition were plotted and their standard deviations calculated using Excel spreadsheets. Percentage of fibers oriented between −15˚ and 15˚ was determined for each normalized image-obtained data. See statistics section below.

Digital imaging analyses (*in vitro*) {#s4-13}
-------------------------------------

16 bit TIFF files corresponding to the maximum projections of assorted monochromatic reconstituted z-stacks were analyzed using MetaMorh Offline software. On the basis of a noise/signal ratio, gray-scale levels of reference images (control) were optimized to reduce background to a minimum while avoiding signal saturation (at the maximum point). An inclusive threshold for positive signal was set for control images. These levels and threshold values were used throughout the entire experiment and served as normalizing controls for each experiment.

Intensity levels of αSMA or active α5-integrin were determined by threshold-masked images, evaluating total pixel intensities and integrated optical densities, using corresponding functions from the software's integrated morphometry analysis (IMA) algorithm. The percentage of αSMA colocalization at F-actin stress fiber structures was calculated by querying αSMA-positive area coverages that overlapped (i.e., co-localized) with phalloidin-positive stress fibers areas.

For experiments questioning levels in murine cells, an 'activated fibroblastic phenotype' was determined by counting the percentage of cells presenting stress-fiber-localized αSMA. Output data from each analysis were normalized to corresponding control conditions and expressed as fold variations related to control.

For 3D-adhesion length calculations: calibrated images (one pixel = 0.11 μm) were used while their gray-scale levels were optimized to reveal 3D-adhesion (i.e., mAb11) positive-stained structures. These were recognized as 'objects' by the software via threshold settings (identical for all images) and measured through the 'dimension' function of IMA. Objects with lengths ≥6.5 μm, signifying *bona fide* 3D-adhesion structures ([@bib18]), were included in the analysis.

The more intricate analyses of multi-labeled 3D-adhesions were performed using the 'line-scan' function of the software. Channel-overlaid 8bit images were subjected to a transversal analysis (12 μm length) to identify peaks of median gray levels of the stated particular markers along the line-scanned structure being analyzed.

*In vitro* SMIA-CUKIE (see '**SMI approach**' below for additional information) was used to query active α~5~-integrin localization (i.e., at or away from 3D-adhesions *in vitro* and where stroma-positive and tumoral-negative locations were identified *in vivo*). Areas corresponding to 3D-adhesion-positive pixels (i.e., mAb11) were assigned as *masks* areas, while SNAKA-51-positive pixels were designated active α~5~-integrin, pFAK^Y397^ as PFAK, and pSmad2/3 S^465,467^/S^423,467^ as PSMAD or *marker* positive areas. *Marker* values corresponding to median, mean, standard deviation, total intensity, integrated intensity and area coverages relative to the *mask,* or relative to the image at *mask,* or away from *mask* locations were obtained as Excel spreadsheet outputs. See below for *in vivo* SMIA-CUKIE analyses using surgical FFPE samples.

Simultaneous multi-channel immunofluorescent (SMI) approach and SMIA-CUKIE software-based analyses {#s4-14}
--------------------------------------------------------------------------------------------------

### Conjugation of Q-dot to primary antibodies {#s4-14-1}

Q-dot antibody labeling kits were from Molecular Probes-ThermoFisher Scientific. SiteClick labeling constitutes a three-step procedure lasting a few days and requires that the desired antibody's carbohydrate domain is modified to allow an azide molecule to be attached to it; In consequence, DIBO-modified nanocrystals are linked to the antibody in question. Each conjugation was carried out strictly as instructed by the protocols provided by the manufacturer. Briefly, approximately 100 µg of antibody was used in each case. Unless there were excessive carrier proteins present in the antibody, there was no need for an antibody pre-purification step. The labeled antibodies were estimated to be at 1 µmolar concentration and stored in sterile conditions at 4°C in light-protected boxes. Sample incubations were all done at a final concentration of \~20 nM or 1:50 dilution (see below).

Immunolabeling of FFPE tissue sections {#s4-15}
--------------------------------------

Slides were exposed to a short-wave UV lamp for about 30 min in a light-protected box to quench auto-fluorescence. They were then kept in a light-protected (i.e., dark) box until used. Sections were deparaffinized in xylene and rehydrated in ascending graded alcohol to water dilutions. Sections were then treated with Digest-All (Invitrogen) and permeabilized in 0.5% TritonX-100. After treating them with blocking buffer as in *in vitro* work (see above), samples were first incubated with the above-mentioned Q-dot pre-labeled antibodies (i.e., Q655 SNAKA51, Q565 mAb11) overnight at 4°C. Sections were washed as in *in vitro* work, and incubated with a mix of mouse monoclonal 'cocktail' containing anti-pan-cytokeratin (clones AE1/AE3, DAKO), anti-EpCam (MOC-31EpCam, Novus Biologicals (Littleton, CO)), and anti-CD-70 (113--16 Biolegend (San Diego, CA) \[[@bib79]\]) to detect epithelial/tumoral locations, together with rabbit monoclonal anti-vimentin (EPR3776, Abcam) antibodies for mesenchymal (stromal) components for 2 hr at RT. Note that pre-incubated Q-dot labeled antibodies could no longer be recognized by secondary antibodies, thus allowing for indirect immunofluorescent detection of tumoral and stromal masks. Secondary antibodies were as used as in *in vitro* work and included donkey anti-mouse Cy2 and donkey anti-rabbit Cy3. Nuclei were stain using Draq-5 (as *in vitro*). Sections were quickly dehydrated in graded alcohol and clarified in Toluene before mounting in Cytoseal-60. Slides were cured overnight at RT before the imaging.

Image acquisitions of FFPE fluorescently labeled sections {#s4-16}
---------------------------------------------------------

FFPE sections of biological samples are known to give strong broad autofluorescence, thus obscuring the specific (labeled) fluorescent signal. To overcome this problem, images were collected using Caliper's multispectral imaging system (PerkinElmer), which utilizes a unique imaging module with Tunable Liquid Crystal. Two different systems namely Nuance-FX (for 40x objective) and Vectra (for 20x objective and high throughput) were used depending on the acquisition needs. A wavelength-based spectral library for each system and each tissue type (i.e., pancreas and kidney) was created by staining control sections with individual fluorophores or by mock treating samples to include the specific autofluorescence spectra. Once a spectral library was constructed for each organ type, it was saved and used for the subsequent image acquisition and analysis. All excitations were achieved via a high-intensity mercury lamp using the following filters (emission-excitation): for Nuance, DAPI (450-720), FITC (500-720), TRITC (580-720), CY5 (680-720); for Vectra, DAPI (440-680), FITC (500-680), TRITC (570-690), CY5 (680-720). For emissions collection, 'DAPI' filter (wavelength range 450--720) was used for all Q-dot labeled markers, while masks used the conventional FITC, TRITC, and CY5 filters. After collecting all image cubes (including all channels), images were unmixed to obtain 16-bit greyscale individual stains monochromatic files. Using Photoshop's \'Levels\' and \'Batch Conversion\' functions, the images were processed in bulk to render identically scaled 8-bit monochromatic images for each channel. The resulting images were sampled to set identical threshold values for each channel, which were used to feed the values needed for analyses in SMIA-CUKIE to signify positive-labeled pixels.

SMIA-CUKIE usage and outputs {#s4-17}
----------------------------

SMIA-CUKIE (SCR_014795) was written for the bulk analysis of high-throughput-acquired monochromatic images, corresponding to simultaneously labeled channels like the ones used in this study. As examples, masks in [Figure 12](#fig12){ref-type="fig"} and [Figure 12---figure supplement 2](#fig12s2){ref-type="fig"} were generated using SMIA-CUKIE and demonstrate how the software isolates stromal locations while omitting positive tumoral areas, based on mask value thresholds that are provided by the user.

Images were sorted into 'Batch Folders', each containing the five monochromatic images corresponding to the original (unmixed) sample. The newly written software, available at <https://github.com/cukie/SMIA_CUKIE>, was created to bulk process and analyze batches of monochromatic images providing localization (masks), intensities, and similar quantifying values (markers), including co-localizations of multichannel monochromatic immunofluorescent (or IHC, etc.) images. The software can identify intersection areas between an unlimited amount of masks, while queried marker values and locations can also be estimated for numerous interrogations. The software requires the identification of common nomenclatures to recognize each type of monochromatic image (i.e vim for vimentin etc.). It also needs information regarding the available number of masks and markers deposited in the batch folders containing the images. In this work, three masks were used corresponding to nuclei, epithelium/tumor and stroma, as well as two markers corresponding to adhesion structures and active α~5~β~1~ integrin. For each of the masks and markers, the software requires a numeric threshold (0-255), which indicates the value of pixel intensity that is to be considered positive for each channel (corresponding to each mask and marker). The software then allows choosing amongst all possible query combinations. Alternatively, it provides an option for the user to write the desired tests to be queried. For example, when active α~5~β~1~ integrin values were requested at *bona fide* stromal locations, the software was instructed to look for 'SNAKA under vimentin, NOTepi/tumor'. In this example, 'SNAKA' was the nomenclature we used for the active integrin channel while vimentin and epi/tumor served as masks. After running this function, the software rendered an Excel file containing values of area coverage for the marker at the requested mask intersection (stroma), as well as total area coverage related to the image. Similarly, values included mean, median, standard deviation, total and integrated intensities. In addition, the software can be instructed to provide image outputs corresponding to requested mask locations, as well as markers shown solely at the corresponding mask intersections (as shown in [Figure 12](#fig12){ref-type="fig"} and [Figure 12 --figure supplement 2](#fig12s2){ref-type="fig"}). Data values obtained in this work are available online at <https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx>. Finally, values were used for statistical analyses as described in the corresponding section.

CRISPR/CAS9-mediated knockout of β~5~ and other integrins in fibroblasts {#s4-18}
------------------------------------------------------------------------

### Immortalization of human fibroblasts {#s4-18-1}

Before performing CRISPR/Cas9-mediated KO of β5 integrin, fibroblasts were immortalized with human telomerase (hTERT) ([@bib17]), using a retroviral infection with the pBABE-neo-hTERT vector, which was a gift from Robert Weinberg (Addgene plasmid \# 1774). First, in order to produce functional retrovirus, packaging cells Phoenix-Amphotropic (φNX) (ATCC \# CRL-3213) at 50% confluence in 10 cm culture dishes were transfected with 10 ug pBABE-neo-hTERT vector using 10 uL Lipofectamine (Invitrogen, \#18324) and 40 uL of Plus Reagent (Invitrogen, \# 11514015) in 6 mL serum/antibiotics free Opti-MEM (Gibco, \# 31985062) culture media overnight at 37°C in a cell culture incubator. The following morning, the medium was replaced with 10 mL fresh Opti-MEM (serum/antibiotics free) and incubated 24 hr at 32°C. In the morning of days 2, 3 and 4 post-transfection, the conditioned medium containing retrovirus was collected and filtered through a 0.45 um syringe filter (Millipore, \#SLHV013SL) and used for subsequent retroviral transfections of fibroblasts. For the viral infection, fibroblasts were cultured in 10 mL of conditioned medium containing the retrovirus (supplemented with 4 ug/mL Polybrene (Santa Cruz, \#sc-134220)) for 8 hr at 37°C. Then cells were washed and incubated with fresh culture medium (DMEM 10% FBS, 1% L-Glut, 1% P/S) and incubated at 37°C overnight. Beginning the next day, this infection procedure was repeated two additional times, for a total of three retroviral infections. Fibroblasts were then selected with G-418 at a concentration of 750 μg/mL until cells grew back to \~90% confluence. Cells were then expanded and tested for overexpression of hTERT, and lack of p16, by western blotting to confirm hTERT overexpression. These cells were used for CRIPSR/CAS9mediated knockout of β5 integrin.

gRNA design {#s4-19}
-----------

To knockout the β5-integrin-subunit-encoding gene from fibroblasts, CRISPR/CAS9 gene editing was performed to introduce a frameshift mutation that disrupts the reading frame causing a premature stop codon to be read, ultimately halting translation and knocking out this gene.

First, gRNAs specific for β5 integrin were designed by targeting exon 3. The first 200 base pairs of exon three were inserted into MIT Optimized CRISPR Design website: <http://crispr.mit.edu/> and the top two scoring gRNAs were selected, based on the presence of a PAM site (a CAS9 recognition site) and limited off-target binding.

The two independent gRNA sequences were as follows:

gRNA1: ACCGAGAGGTGATGGACCGT

gRNA 2: CACCGAGAGGTGATGGACCG

For a non-targeting gRNA control, the following gRNA against eGFP was designed: CATGTGATCGCGCTTCTCGT.

Generation of lentiviral KO vector {#s4-20}
----------------------------------

Once the gRNA sequences were designed and ordered (Integrated DNA Technologies), they were cloned into the LentiCRISPR v2 vector (LentiCRISPR v2 was a gift from Feng Zhang; Addgene plasmid \# 52961) ([@bib80]). This is a dual-expression vector, expressing the CRISPR/CAS9 protein as well as the cloned gRNA sequence driven by the human U6 promoter. Briefly, DNA oligos representing the gRNA sequences are listed below, with overhangs compatible with the Esp3I restriction enzyme (**[bold, underlined)]{.ul}**and an additional G added to the beginning of each gRNA, with a complementary C on the reverse oligo (***bold, italics***), for efficient transcription driven by the human U6 promoter.

Integrin β~5~ gRNA 1.1**[CACC]{.ul}*G***ACCGAGAGGTGATGGACCGTIntegrin β~5~ gRNA 1.2[**AAAC**]{.ul}ACGGTCCATCACCTCTCGGTCIntegrin β~5~ gRNA 2.1**[CACC]{.ul}*G***CACCGAGAGGTGATGGACCGIntegrin β~5~ gRNA 2.2[**AAAC**]{.ul}CGGTCCATCACCTCTCGGTGCeGFP gRNA 1.1**[CACC]{.ul}*G***CATGTGATCGCGCTTCTCGTeGFP gRNA 1.2[**AAAC**]{.ul}ACGAGAAGCGCGATCACATGCIntegrin α~5~ gRNA 1.1**[CACC]{.ul}*G***CTCAGTGGAGTTTTACCGGCIntegrin α~5~ gRNA 1.2[**AAAC**]{.ul}GCCGGTAAAACTCCACTGAGCIntegrin α~5~ gRNA 2.1**[CACC]{.ul}*G***TCAGTGGAGTTTTACCGGCCIntegrin α~5~ gRNA 2.2**[AAAC]{.ul}**GGCCGGTAAAACTCCACTGACIntegrin α~v~ gRNA 1.1**[CACC]{.ul}*G***ATTCAATTGGCTGGCACCGGCGGIntegrin α~v~ gRNA 1.2[**AAAC**]{.ul}CCGCCGGTGCCAGCCAATTGAATCIntegrin α~v~ gRNA 2.1[**CACC**]{.ul}***G***TGACTGGTCTTCTACCCGCCGGIntegrin α~v~ gRNA 2.2[**AAAC**]{.ul}CCGGCGGGTAGAAGACCAGTCACCIntegrin β~3~ gRNA 1.1[**CACC**]{.ul}*G*CCCAACATCTGTACCACGCGIntegrin β~3~ gRNA 1.2[**AAAC**]{.ul}CGCGTGGTACAGATGTTGGGCIntegrin β~3~ gRNA 2.1[**CACC**]{.ul}*G*ACCTCGCGTGGTACAGATGTIntegrin β~3~ gRNA 2.2[**AAAC**]{.ul}ACATCTGTACCACGCGAGGTC

Next, the gRNA oligos stocks were diluted to 100 uM, and 1 uL of each gRNA pair was added to a T4 PNK reaction mixture (NEB, \#M0201S) for a 10 uL reaction. The reaction was allowed to run in a thermal cycler to phosphorylate and anneal the oligos, according to the following program:

1.  37°C for 30 min

2.  95°C for 5 min

3.  Decrease 5°C every minute until 25°C

To prepare the vector for cloning, 5 ug of LentiCrispr v2 vector were simultaneously cut with Fast Digest Esp3I (ThermoFisher, \#FD0454) and dephosphorylated with Fast AP (ThermoFisher, \#EF0651) for 30 min at 37°C and subsequently run on a 1.5% agarose gel and purified for cloning using the GeneJet Gel Extraction Kit (Thermofisher, \#K0691).

To clone the annealed gRNA oligos into the vector, the oligos were diluted 1:200 in RNAase-free water (ThermoFisher, \#4387937), and added to the quick ligation reaction mixture (NEB, \#M2200S), along with 1 µL of the digested and dephosphorylated vector, and the reaction was allowed to proceed for 10 min at room temperature.

For bacterial transformation, 2 µL of the reaction was mixed with 50 µL of competent Stbl3 strain of *Escherichia coli* for 30 min on ice. The bacteria were then heat shocked for 45 s at 42°C and immediately transferred to ice for 2 min. Then, 50 µL of the transformed bacteria were spread onto an LB/agar dish containing 100 µg/mL ampicillin and incubated at 37°C overnight.

The next day, single colonies were screened by colony PCR using the U6 promoter forward primer: GAGGGCCTATTTCCCATGATT and the corresponding reverse gRNA primers (gRNA x.2). Positive clones were selected to expand for plasmid purification and sequencing.

CRISPR lentivirus production {#s4-21}
----------------------------

For functional lentiviral production, viruses were generated in 293T cells using the cloned LentiCrispr v2 plasmids, and two packaging plasmids: psPAX2 (psPAX2 was a gift from Didier Trono; Addgene plasmid \# 12260) and VSVg. Briefly, 10 µg of cloned LentiCrispr V2, 5 µg of psPAX2, and 2 µg of VSVg were mixed in 1 mL serum-free/antibiotic-free DMEM in an 1.5 mL Eppendorf tube. 30 µL of X-treme Gene 9 (Roche, \#06365787001) was added to the DNA mixture and gently mixed with the pipette tip. The mixture was allowed to sit for 45 min at room temperature. Next, the mixture was added drop-wise to a T75 flask containing 5 mL serum-free/antibiotic-free DMEM and 293T cells at \~85% confluence and slowly rocked for 30 s to evenly mix the DNA transfection mixture. The next morning, the serum-free media was removed from the 293T cell flasks, and 10 mL of fresh DMEM containing 10% FBS and 1% penicillin/streptomycin were added to each flask. Two days and 4 days post-transfection, the medium was collected and filtered through a 0.45 µM syringe filter (Millipore, \#SLHV013SL) and then used immediately for viral infection of target cells, or stored at −80°C until needed.

CRISPR lentiviral infection {#s4-22}
---------------------------

Target cells (naïve or desmoplastic fibroblasts) were seeded at \~40% confluence in 2 mL complete fibroblast media in a six-well plate. The following day, the target cells were infected with 2 mL of lentivirus for each corresponding CRISPR construct (eGFP or integrin gRNAs) in the presence of 10 ug/mL Polybrene (Santa Cruz, \#sc-134220). As a control for the infection, cells were infected with a lentivirus overexpressing GFP, and the appearance of GFP-positive cells signified a successful infection. 24 hr later, the medium was replenished with fresh complete medium for each cell type. After 72 hr, puromycin selection (1 ug/mL for naïve fibroblasts, 2 ug/mL for desmoplastic fibroblasts) of the infected cells began. The selection process lasted between 7 and 10 days; cells were expanded, and the efficiency of CRISPR/CAS9 knockout was assessed by western blotting. The cell lines with the greatest degree of target protein knockout were used for subsequent experiments.

SDS-PAGE/western blotting {#s4-23}
-------------------------

Briefly, various normal fibroblasts and CAFs were grown to confluency in six-well plates and were lysed in standard RIPA buffer. Lysates were then homogenized by sonication, allowed to rest on ice for 15 min, and centrifuged for 10 min at maximum speed in a microcentrifuge. Next, samples were diluted in 2x loading buffer (Bio-Rad, Hercules, CA), boiled for 3 min, and loaded onto 4--20% gradient gels (Bio-rad, Hercules, CA) and run at 70 volts for 2 hr. Next, gels were subjected to semi-dry transfer to PVDF membranes (Millipore, Billerica, MA) and blocked for 1 hr at RT in 5% milk in 0.1% TBST. Membranes were then incubated in the one of the following primary antibodies overnight at 4°C: rabbit polyclonal anti-α~v~-integrin (AB_2631308) (1:5000) (Mybiosource, San Diego, CA), rabbit monoclonal anti-α~5~-integrin (AB_2631309) (1:1000) (Abcam, Cambridge, MA), rabbit polyclonal anti-β~5~-integrin (AB_10806204) (1:1000) () (Millipore, Billerica, MA) or rabbit polyclonal anti-β~3~-integrin (1:1000) (AB_91119) (Millipore, Billerica, MA). The following day, membranes were washed in 0.1% TBST, 5 times for 5 min each. Next, membranes were incubated for 2 hr in anti-rabbit IgG-HRP secondary antibodies (Sigma, St. Louis, MO) in 5% milk in 0.1% TBST. Blots were then washed again five times/5 min each. Finally, Immobilon Western Chemiluminescent HRP substrate (Millipore, Billerica, MA) was added to the blots and protein bands were captured by film or Protein Simple Digital Imaging System (Protein Simple, San Jose, CA).

Bioinformatics and statistics {#s4-24}
-----------------------------

Two-tailed non-parametric Mann-Whitney tests were used to query experimental significances for all *in vitro* data, comparing control conditions to experimental ones independently. All *in vitro* results were presented as medians with interquartile range. Each PDAC-related *in vitro* experiment was performed at least three times, using one patient matched CAF and normal fibroblasts. For verification, these series of experiments were also conducted, using one additional pair of normal and activated fibroblasts from a non-related patient, two normal fibroblasts isolated from two additional non-related patients, and one tumor tissue which provided one additional non-related activated (desmoplastic) fibroblastic cell. All cells characterized as normal fibroblasts were verified for their phenotype and challenged with D-ECMs produced by CAFs isolated from three of the above describedpatients. These included a total of five different patient sources which included seven surgical samples. The RCC-related *in vitro* assessments were performed employing a combination of two patients-derived CAFs and normal fibroblasts from another two different sources. All the image analyses were conducted in at least ten images containing no less than three cells per region per experimental condition for each above-mentioned repetition.

Regarding statistics pertinent to the TMAs, to identify clinical and laboratory variables related to patient survival (OS, DSS, and RFS), univariate and multivariable analyses were performed by constructing decision trees using the CART methodology. Clinical and laboratory variables were considered as predictors of survival time and are listed in data uploaded to <https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx>. The unified CART framework that embeds recursive binary partitioning into the theory of permutation tests was used. Significance-testing procedures were applied to determine whether no significant association between any of the clinical variables and the response could be stated, or whether the recursion would need to stop. Also, log-rank tests and univariate and multivariable Cox proportional hazards (PH) were used to correlate clinical and laboratory variables with survival; hazard ratios (with 95% confidence intervals) were calculated, as appropriate, for various comparisons. Goodness-of-fit of the PH model was evaluated based on Schoenfeld residuals. In order to account for potential batch effects, a 'batch' variable was included as an adjustment variable in all the analyses that were pertinent to the PDAC cohort. All tests were two-sided and used a significance level of 5% to test each hypothesis. Significant p-values in all figures were denoted by asterisks as follows: \*\*\*\*p\<0.0001 extremely significant, \*\*\*p=0.0001--0.01 very significant, \*\*p=0.01--0.05 significant and \*p=0.05--0.10 marginally significant. Statistical analyses were performed using GraphPad Prism software, version 6.05 for Windows (La Jolla, CA) and the R packages *survival* and *parity* ([www.r-project.org](http://www.r-project.org)).
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Matrix-regulated integrin αvβ5 maintains α5β1-dependent desmoplastic traits prognostic of neoplastic recurrence\" for consideration by *eLife*. Your article has been favorably evaluated by Harry Dietz (Senior Editor) and three reviewers, one of whom, Johanna Ivaska, is a member of our Board of Reviewing Editors. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

A timely and critical question in cancer biology concerns the dual role of the fibroblasts in restraining disease in some instances (i.e. normal fibroblasts) while promoting disease progression in other instances (i.e. activate carcinoma-associated fibroblasts). In particular, recent studies evaluating pancreatic cancer have highlighted this issue by further confirming that normal fibroblasts can restrain disease; findings that have been reasonably well described in other solid tumors. Further, strong consensus evidence in pancreatic cancer and numerous other solid tumors indicates a disease promoting role for activated myofibroblasts in the stroma. In the current work the authors undertake focused studies to evaluate this dual role of fibroblasts and elucidate fundamental mechanisms driving these distinct behaviors. Franco-Barraza and colleagues have investigated the underlying mechanisms of PDAC desmoplasia by generating 3D in vitro cell derived matrixes from normal fibroblasts (to generate N-ECM) and PDAC CAFs to generate D-ECM (desmoplastic ECM). They find that TGFb signalling is essential for D-ECM production but dispensable for the ability of the D-ECM to covert naïve fibroblasts to activated myofibroblasts. They find that in response to PDAC-associated D-ECM, αvβ5-integrin re-distributes active α5β1-integrin away from pFAK-Y397 positive 3D-adhesions and, thus, promotes myofibroblastic activation whereas inhibition of avb5 under these conditions was protective against myofibroblasts activation by increasing active a5b1 location to the cell surface. They also have data from human PDAC and RCC investigating whether levels of FAK and α5β1 integrin can distinguish tumor suppressive v tumor promoting stroma.

Essential revisions:

The reviewers found your work to be particularly relevant to the field right now as there is some controversy about the role of fibroblasts in disease progression and response to therapy. They felt that the data presented in the submitted manuscript are very timely and may help clarify the dynamics of cancer stroma crosstalk in pancreatic carcinoma. However, all of the reviewers found the manuscript to be extremely dense and especially the Results section very hard to follow. Their enthusiasm was somewhat hampered by the lack of clarity in several instances (please see specific points below) that make portions of the manuscript difficult to read/interpret. Furthermore, they were critical about the clinical relevance and strength of the human data and the representability of the limited number of fibroblasts for PDAC as a whole. In addition, to the specific points raised below the authors are strongly encouraged to significantly edit and rewrite the manuscript to improve clarity of presentation, understanding what has been done and the logic behind the experiments.

1\) PDAC is a highly heterogeneous disease, but the authors have studied fibroblasts from only 3 tumors, and they seem to have presented data from only 1 tumor (although they may have repeated with fibroblasts from the other 2 tumors these data aren\'t shown). The authors are encouraged to re-write the manuscript to show very clearly the data from the fibroblasts from the 3 different patients. This would make a more understandable story but also give clearer insights into the heterogeneity they might be seeing (i.e. are there differences from the 3 tumours when they have characterised the fibroblasts in depth?).

2\) The human data, particularly from PDAC patients, need to be clarified. It is unclear why 10 PDAC patients (and 10/11 RCC patients) are excluded. However, the most obvious problem is that since there was no effect of stromal active α5β1 levels on OS, the authors have compared RFS -- but apparently half of the cohort had a RFS of 0 (even though many have a OS of years!). Combined with the seemingly arbitrary cut-off for low vs. high (rather than above and below median which might be considered standard), this effectively leaves 3 patients with low stromal active α5β1 at 3D-adh. The authors then claim RFS benefits of about 11 months with high stromal active α5β1 at 3D-adh, but the median of those patients is about 11 months, compared with the survival of the 3 \'low\' patients at 10, 10 and 19 months.

In addition, despite assessing levels of α5β1 away from 3D-adh, and pFAK and pSmad, the relationship to OS or RFS is not shown or discussed, leading the reader to presume the data were negative. Far from supporting the conclusions of the in vitro work, this section raises questions as to the relevance to cancer.

It also appears highly likely that the patient samples used in [Figure 13](#fig13){ref-type="fig"} etc. represent a subset of pancreatic cancer patients (i.e. the \~20% that are candidates for surgical resection). Thus, they may not fully represent the patient population and some of the most aggressive forms of the disease. Some discussion of this seems appropriate.

3\) The TGF-β experiments described starting in [Figure 1](#fig1){ref-type="fig"} are interesting and insightful but also raise a number of important questions that are not adequately addressed or discussed in the manuscript in its current form. For instance, what is really changing when TGF-β signaling is blocked? Are the activated myofibroblasts in general reverting to a more phenotypically quiescent state, is ECM secretion changing resulting in fundamentally different ECM composition, are the CAFs simply less contractile or polarized etc.? While this reviewer fully understands that each of these factors cannot be examined in detail in the current work, a more encompassing discussion of these potential shifts would improve the manuscript. Likewise, if data exists from evaluating these cultures over time it would strengthen the manuscript. Further, the data suggests that the differential influence of the N v D ECM is largely due to the differences in ECM alignment. Can a case be made that this is the dominant factor or one of the critical factors?

4\) How effective are the employed antibodies at reducing integrin activity in each instance? The consistently intermediate (trending yet non-significant) levels of SMA following inhibition of alpha5-beta1 are a bit perplexing and generate some concern the that inhibition is simply weak. As such the CRISPR data is appreciated, however it would appear to be much more insightful to also have an approach to knockdown alpha5-beta1 levels.

5\) Currently, very little mechanistic insight is provided into the underlying mechanism of altered integrin traffic. While defining the exact mechanism of how a5v5 inhibition drives increased a5b1 localization to 3D adhesion is probably too much to ask a few obvious things could be done. i) Given the high level of expertise in imaging demonstrated in the manuscript the authors should be able to describe the intracellular localization of the active a5b1 with more accuracy (are these early endosomes, recycling endosomes...). ii) There is a wealth of literature in cancer cells showing that inhibition of avb3 integrin with osteopontin, cilengitide or cRGD drives a5b1 recycling from intracellular endosomes to the membrane. Could a similar mechanism be involved in the ALULA-driven increase of a5b1 in 3D adhesions? This should be at least discussed.
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Author response

*Essential revisions:*

*The reviewers found your work to be particularly relevant to the field right now as there is some controversy about the role of fibroblasts in disease progression and response to therapy. They felt that the data presented in the submitted manuscript are very timely and may help clarify the dynamics of cancer stroma crosstalk in pancreatic carcinoma. However, all of the reviewers found the manuscript to be extremely dense and especially the Results section very hard to follow. Their enthusiasm was somewhat hampered by the lack of clarity in several instances (please see specific points below) that make portions of the manuscript difficult to read/interpret.*

We acknowledge the initially submitted manuscript was extremely dense, reflecting the large amount of data included (which has now expanded further, as outlined below), and the complexity of the analysis. We have completely rewritten the manuscript, paying particular attention to the Results section, and hope that the text is now much more clear.

*Furthermore, they were critical about the clinical relevance and strength of the human data.*

This is a very important point. Due to the efforts of our clinical collaborators, we were able to double the number of patients represented in the PDAC cohort (see specific answers to points made by each reviewer below for particulars). The inclusion of these additional specimens, presented in a new Figure ([Figure 13](#fig13){ref-type="fig"} and [Figure 13---figure supplements 1](#fig13s1){ref-type="fig"}--[2](#fig13s2){ref-type="fig"}), now allows us to draw statistically robust conclusions that support our overall hypothesis.

*And the representability of the limited number of fibroblasts for PDAC as a whole.*

Our data now includes quantitative assessments of cells harvested from 5 PDAC patients. These include 2 patients for whom we obtained matching normal fibroblastic cells and cancer associated fibroblasts (CAF), as well as one additional patient-derived set of CAFs and two unpaired normal pancreatic stellate cells. This made up for 7 different populations of primary cells being assessed (in contrast to the previous focus placed mostly in only one pair in the original submission). We tested all normal cells for their response to desmoplastic-ECM (D-ECM) and tested all D-ECMs for their phenotype and function, and for each, evaluated the ability of a TGFbeta receptor inhibitor during matrix production to reverse their ability to produce functional D-ECM (see new [Table 2](#tbl2){ref-type="table"} and new [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). These added analyses buttressed the idea that the signaling we observe is generalizable for describing interactions between naïve pancreatic stellate cells and CAF-produced, PDAC-associated D-ECMs.

*In addition, to the specific points raised below the authors are strongly encouraged to significantly edit and rewrite the manuscript to improve clarity of presentation, understanding what has been done and the logic behind the experiments.*

As noted above, the entire manuscript has been rewritten to increase clarity.

1\) PDAC is a highly heterogeneous disease, but the authors have studied fibroblasts from only 3 tumors, and they seem to have presented data from only 1 tumor (although they may have repeated with fibroblasts from the other 2 tumors these data aren\'t shown). The authors are encouraged to re-write the manuscript to show very clearly the data from the fibroblasts from the 3 different patients. This would make a more understandable story but also give clearer insights into the heterogeneity they might be seeing (i.e. are there differences from the 3 tumours when they have characterised the fibroblasts in depth?).

We thank the reviewers for this comment. We have now included quantitative data comparing phenotypes from 3 sets of CAFs and 4 sets of naïve fibroblasts for multiple reported parameters, clearly noting that all specimens are analyzed. Statistical analysis of phenotypes indicates limited issues with heterogeneity, although certainly, the differences observed in this study between signaling pathways required for CAF functions versus regulation of naïve fibroblast-to-myofibroblastic activation may explain some *in vivo* observed stroma heterogeneity. These tests included measurement of matrices produced in the presence or absence of inhibition of the TGFbeta pathway for their ability to induce myofibroblastic features (including levels and localization of α-smooth muscle actin) in naïve fibroblastic stellate cells. Results from the multiple cell-matrix combinations (new [Table 2](#tbl2){ref-type="table"} and new [Figure 2---figure supplement 1](#fig2s1){ref-type="fig"})are now bolstered by results from other model systems (revised [Figure 3](#fig3){ref-type="fig"} and [Figure 11](#fig11){ref-type="fig"} together with [Figure 11---figure supplements 1](#fig11s1){ref-type="fig"}--[6](#fig11s6){ref-type="fig"} as well as revised [Table 5](#tbl5){ref-type="table"}) and supported by statistically significant analysis of a larger number of clinical PDAC samples that show similar signaling relationships (new [Figure 13](#fig13){ref-type="fig"} and new [Figure 13---figure supplements 1](#fig13s1){ref-type="fig"}--[2](#fig13s2){ref-type="fig"}).

*2) The human data, particularly from PDAC patients, need to be clarified. It is unclear why 10 PDAC patients (and 10/11 RCC patients) are excluded.*

A\) A small number of patients were excluded from the cohorts analyzed in the initial submission because we did not have annotation for their OS, RFS or DSS. The numbers of patients used for each analysis are now clearly annotated in a new [Table 6](#tbl6){ref-type="table"}. In addition, please note that we were able to extend analysis to include additional PDAC patients, so that the total number of specimens analyzed in this revision now totals 128 tumors (versus 65 in the original submission), with new results presented in [Figure 13](#fig13){ref-type="fig"} and [Figure 13---figure supplements 1](#fig13s1){ref-type="fig"}--[2](#fig13s2){ref-type="fig"}. We have available OS information for all PDAC patients, and for 116/126 RCC patients.

B\) In regard to analysis of RFS or DSS, we do not have any annotation regarding evidence of disease following surgery for 26 PDAC patients, so that only 102/128 PDAC patients are analyzed for this property in this revision. Similar lack of annotation caused us to only analyze DSS in 115/126 RCC patients.

C\) We have made a comprehensive summary of available data (regarding age, gender and other clinical and history particulars of the complete PDAC and RCC patient cohorts, as well as more than 50 biomarker readouts from the simultaneous multi-color immunofluorescent (SMI) approach, available online in a linked database (<https://www.foxchase.org/sites/fccc/files/assets/cukierman_Franco-Barraza%20SMIA-CUKIE-Dec-2016.xlsx>), to ensure complete transparency and to support future in silico searches.

*However, the most obvious problem is that since there was no effect of stromal active α5β1 levels on OS, the authors have compared RFS -- but apparently half of the cohort had a RFS of 0 (even though many have a OS of years!).*

We acknowledge the issue with RFS was problematic, and in the modified Results section discuss limitations of the dataset directly. We believe that part of the difficulty in achieving significance lies in size of the sample cohorts, and part in the fact that localization of the active integrin conformation to intracellular vesicles versus at the PM emerged in this study as a critical factor, which it is more difficult to robustly image in primary tumor specimens. In this revision, we have enlarged our analytic cohort of PDAC specimens (making the RFS data more reliable), and analyzed more markers that are less subject to localization control, and hence potentially more robust. We now clearly show that active TGFbeta signaling, represented by levels of pSMAD2/3 at stromal (but not tumor) locations, correspond with significantly lower OS times. Statistical analysis indicates that SMAD2/3 and active α~5~β~1~-integrin at 3D adhesion positive areas were each separately significant in prediction of RFS, even given the limitations of the data set. We believe that future studies using larger numbers of samples and examining additional markers will result in significant protective OS outcomes, since we did observe some trends which did not reach statistical significance.

*Combined with the seemingly arbitrary cut-off for low vs. high (rather than above and below median which might be considered standard), this effectively leaves 3 patients with low stromal active α5β1 at 3D-adh. The authors then claim RFS benefits of about 11 months with high stromal active α5β1 at 3D-adh, but the median of those patients is about 11 months, compared with the survival of the 3 \'low\' patients at 10, 10 and 19 months.*

Addressing the statement about seemingly arbitrary partitioning of the data used to create Kaplan-Meier curves, in the "Bioinformatics and Statistics" section of Materials and methods, we now clearly state how we use a unified CART framework that embeds recursive binary partitioning into the theory of permutation tests. As defined by our biostatistician, significance-testing procedures were applied to determine whether no significant association between any of the clinical variables and the response could be stated, or whether the recursion would need to stop. This approach is commonly used for this type of analyses by clinical biostatisticians. Median partitioning of the data was also queried in the univariate and multivariate testing we conducted, but rendered no significant results with regards to the 7 markers.

*In addition, despite assessing levels of α5β1 away from 3D-adh, and pFAK and pSmad, the relationship to OS or RFS is not shown or discussed, leading the reader to presume the data were negative. Far from supporting the conclusions of the* in vitro *work, this section raises questions as to the relevance to cancer.*

In the first submission of the manuscript, these data were not significant for PDAC and hence not discussed. However, due to the much-enhanced PDAC patient cohort analyzed for this revision, some of these values are indeed now significant for prediction of OS, including notably the stromal increases in pSMAD2/3. These results are now shown in new [Figure 13](#fig13){ref-type="fig"} and are included in the new Discussion section. Moreover, three independent SMIA-CUKIE quantitative analyses each implicated α5β1 activity and in particular its stromal localization at 3D-adhesions (new [Figure 13---figure supplement 2](#fig13s2){ref-type="fig"}), and nowprovide a stronger support for the relevance of *in vitro* data to pancreatic cancer in patients. Similarly, this revision now includes all significant Kaplan-Meier curves analyzing biomarkers in RCC patients, and better supports the pathophysiological validity of the *in vitro* 3D stroma system.

*It also appears highly likely that the patient samples used in ([Figure 13](#fig13){ref-type="fig"} etc. represent a subset of pancreatic cancer patients (i.e. the \~20% that are candidates for surgical resection). Thus, they may not fully represent the patient population and some of the most aggressive forms of the disease. Some discussion of this seems appropriate.*

We agree that PDAC patients that are surgical candidates typically do not have the most advanced disease, as we now clearly state in the Results and Legends to [Figure 13](#fig13){ref-type="fig"} and to [Figure 13---figure supplements 1](#fig13s1){ref-type="fig"}--[4](#fig13s4){ref-type="fig"}, and comment on in the Discussion. In this context, we view it as compelling that in spite of the bias of our analytic cohorts to earlier stage patients, differences in OS and/or RFS were evident correlating with some of the markers we analyzed.

*3) The TGF-β experiments described starting in [Figure 1](#fig1){ref-type="fig"} are interesting and insightful but also raise a number of important questions that are not adequately addressed or discussed in the manuscript in its current form. For instance, what is really changing when TGF-β signaling is blocked? Are the activated myofibroblasts in general reverting to a more phenotypically quiescent state, is ECM secretion changing resulting in fundamentally different ECM composition, are the CAFs simply less contractile or polarized etc.? While this reviewer fully understands that each of these factors cannot be examined in detail in the current work, a more encompassing discussion of these potential shifts would improve the manuscript. Likewise, if data exists from evaluating these cultures over time it would strengthen the manuscript. Further, the data suggests that the differential influence of the N v D ECM is largely due to the differences in ECM alignment. Can a case be made that this is the dominant factor or one of the critical factors?*

We agree that the mechanism of TGFbeta regulation is important. Given the constraints of fitting additional information into an already very long manuscript, we have now included a new paragraph in the Discussion providing context from recent studies addressing a proposed positive feedback loop between TGFbeta accessibility and regulation of myofibroblastic activation during chronic fibrosis (and desmoplasia). The Discussion includes examples in which this signaling has been directly associated to anisotropic ECM production as well as ECM alignment features being independently indicative of deteriorating patient outcomes (e.g., publications by Klingberg (JCB, 2014), Achterberg (J Invest Dermatol, 2014), Conklin (AJP, 2011) and Bredfeldt (J Pathol Inform., 2014). Our data does not allow us to make definitive statements about changes of protein composition of ECMs arising from TGFbeta inhibition, although we do state that induction of collagen I and the differential spliced form of fibronectin are known traits of desmoplasia.

*4) How effective are the employed antibodies at reducing integrin activity in each instance? The consistently intermediate (trending yet non-significant) levels of SMA following inhibition of alpha5-beta1 are a bit perplexing and generate some concern the that inhibition is simply weak. As such the CRISPR data is appreciated, however it would appear to be much more insightful to also have an approach to knockdown alpha5-beta1 levels.*

A\) We thank the reviewers for this comment, as it resulted in a significant change to the study (see below comments about newly generated mutant fibroblasts). Regarding the specificity of the functional antibodies: these antibodies are broadly used and very well accepted in the field. We now state this fact and cite references to the work that defined the functional properties of these valuable reagents.

B\) In spite of the specificity of the reagents, we now also clearly acknowledge at multiple places in the text the fact that inhibition using antibodies is transient, while genetic ablation negates receptor expression, which may be impact alternative functions, making the two types of assay non-equivalent. For example, the revised text now includes a statement that gross expression of several of the integrins analyzed is needed for naïve-to-myofibroblastic activation in response to D-ECM, while α~5~β~1~-integrin activity, regulated by α~v~β~5~-integrin, opposes D-ECM stimulation of this transition.

C\) We acknowledge the reviewer's point regarding the intermediate levels of α-SMA, but we do not believe that the reason for α-SMA levels being less affected than its F-actin localization are due to antibodies presenting a weak inhibitory effect. Rather, we believe that signaling between alphavbeta5 and alpha5beta1 is important for maintaining α-SMA at stress fibers, but not for its expression, in naïve cells responding to D-ECM, while levels of α-SMA expression instead depend on TGFbeta signaling, and that the intermediate levels we see reflect the complexity of the signaling stimuli. This fact is generally supported by the findings that alphaSMA mRNA levels are unaffected by overnight D-ECM incubation of naïve fibroblasts while high levels of α-SMA expression are necessary in CAFs producing D-ECMs. The revised Discussion section now also cites work related to the complexity of control of α SMA: for instance, evidence that α~5~β~1~-positive elongated 'super mature' adhesion structures, known to control tension-dependent recruitment of αSMA to stress fibers while not affecting protein levels, play important functional roles in myofibroblasts.

D\) We agree with the reviewers asking for knockout (CRISPR) inclusion of alpha5 fibroblasts (both in naïve fibroblastic stellate cells and in CAFs). Indeed, we now include not only these mutants, but also mutants for alphav as well as beta3 integrins, in both normal fibroblasts and CAFs. Extensive data comparing these new models are presented in new [Figure 3---figure supplements 1](#fig3s1){ref-type="fig"}--[2](#fig3s2){ref-type="fig"}, [Figure 4---figure supplements 2](#fig4s2){ref-type="fig"}--[3](#fig4s3){ref-type="fig"}, [Figure 5---figure supplement 5](#fig5s5){ref-type="fig"}, [Figure 7](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}, [Figure 10](#fig10){ref-type="fig"} and [Figure 10---figure supplement 1](#fig10s1){ref-type="fig"}. Some of the added text emphasizes the fact that results using mutants recapitulated results using inhibitors, while others highlight specific differences, providing improved mechanistic detail to the study.

*5) Currently, very little mechanistic insight is provided into the underlying mechanism of altered integrin traffic. While defining the exact mechanism of how a5v5 inhibition drives increased a5b1 localization to 3D adhesion is probably too much to ask a few obvious things could be done. i) Given the high level of expertise in imaging demonstrated in the manuscript the authors should be able to describe the intracellular localization of the active a5b1 with more accuracy (are these early endosomes, recycling endosomes...). ii) There is a wealth of literature in cancer cells showing that inhibition of avb3 integrin with osteopontin, cilengitide or cRGD drives a5b1 recycling from intracellular endosomes to the membrane. Could a similar mechanism be involved in the ALULA-driven increase of a5b1 in 3D adhesions? This should be at least discussed.*

A\) We have added a new section to the revised manuscript to analyze the intracellular location(s) of alpha5beta1 integrin. This analysis indicated accumulation of this activated integrin in late endosomes (Rab7- and Rab11-positive) and multivesicular (CD81-positive) endosomes (new [Figure 9](#fig9){ref-type="fig"}), but not early endosome positive for AAE1 and Rab5. In addition, in new electron microscopy images using the same experimental conditions, we utilized double immunogold to detect 3D-adhesion locations versus active alpha5beta1 (new [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). This analysis indicates the intracellular integrin activity induced by D-ECM by naïve fibroblastic cells does not correspond to clatherin coated generated endosomes, and that multivesicular endosomes positive with this integrin are lost upon beta5integrin ablation.

B\) We thank the reviewers for bringing to our attention previous work showing integrin regulation in receptor recycling. We have now cited relevant literature, and included a statement to the fact that integrin binding ligands such as soluble RGD, osteopontin and cilengitide have been shown to induce integrin crosstalk between α~v~β~3~ and α~5~β~1~ resulting in the association of α~5~β~1~ with Rab-coupling protein, which regulates its localization concomitant with EGFR. Besides citing the work that provided this data, we mention the possibility that the use of antibodies to inhibit avb5 integrin activity in this study may have triggered activation of the Rab cellular trafficking machinery, which is otherwise restricted by α~v~β~5~ activity during tumor-associated desmoplasia, which could explain the observed accumulation of α~5~β~1~ to late endosomes.

[^1]: Values obtained from naïve cells (pancreatic stellate cells isolated from patient \#1) cultured overnight within intact D-ECMs (made from CAFs isolated from patient \#1) were used for normalization and assigned an arbitrary unit of 1.00. Assorted, patient \#1 derived, ECMs were intact **N-ECM** or intact **D-ECM** while experimental conditions included D-ECMs made by CAFs treated with SB-431542 (**D+TGFβi**) or DMSO (**D+DMSO**) during ECM production. Note that quantitative immunofluorescent obtained values of αSMA and F-actin were used to calculate stress fiber localization and expression of **αSMA**.

[^2]: P values, listed below, were calculated using the two-sided and two-tailed Mann Whitney test needed for normalized data.

[^3]: N-ECM vs. D-ECM; **p\<0.0001** stress fiber localization; **p\<0.0001** expression.

[^4]: N-ECM vs. D+TGFβi; p=0.8847 stress fiber localization; **p=0.0002** expression.

[^5]: N-ECM vs. D+DMSO; **p=0.0036** stress fiber localization; **p\<0.0001** expression.

[^6]: D-ECM vs. D+TGFβi; **p\<0.0001** stress fiber localization; **p=0.0198** expression.

[^7]: D-ECM vs. D+DMSO; p=0.3578 stress fiber localization; p=0.1208 expression.

[^8]: D+TGFβi vs. D+DMSO; **p\<0.0001** stress fiber localization; p=0.6236 expression.

[^9]: Values obtained from **naïve** cells (e.g., inactive stellate cells) isolated from patient number '**\#2**' cultured overnight within **D-ECMs** made from CAFs isolated from patient **\#1** were used for normalization and assigned an arbitrary unit of 1.00. Assorted, naïve cells (patient numbers indicated) were cultured within **D-ECMs** derived from the indicated CAFs, while experimental conditions included assorted D-ECMs treated with SB-431542 (**D+TGFβi**) during ECM production. Note that quantitative immunofluorescent obtained values of αSMA and F-actin were used to calculate stress fiber localization and expression of **αSMA**. P values, listed below, were all calculated using the Mann Whitney test, compared to the normalized (2)/(1) experimental condition, to account for non-paired, two-tailed and non-Gaussian distributions of the data.

[^10]: (2)/(1) vs. (2)/(2); **p=0.0836** stress fiber localization; **p=0.3825** expression.

[^11]: (2)/(1) vs. (3)/(2); p=0.1680 stress fiber localization; **p=0.1736** expression.

[^12]: (2)/(1) vs. (4)/(1); **p=0.4266** stress fiber localization; **p=0.0755** expression.

[^13]: (2)/(1) vs. (4)/(5); **p=0.8927** stress fiber localization; **p=0.7509** expression.

[^14]: (2)/(1) vs. (2)/(5); p=0.1885 stress fiber localization; p=0.4192 expression.

[^15]: (2)/(1) vs. (2)/(1**+**TGFβi); **p\<0.0001** stress fiber localization; p\<0.0001 expression.

[^16]: (2)/(1) vs. (2)/(5+TGFβi); **p=0.0909** stress fiber localization; p=0.0040 expression.

[^17]: (2)/(1) vs. (3)/(1+TGFβi); **p=0.0018** stress fiber localization; p\<0.0001 expression.

[^18]: (2)/(1) vs. (4)/(5+TGFβi); **p=0.1018** stress fiber localization; p=0.5181 expression.

[^19]: Values obtained from naïve cells cultured overnight within intact D-ECMs were used for normalization (as shown in [Table 1](#tbl1){ref-type="table"}) and assigned an arbitrary unit of 1.00. **TGFβ-i** is the experimental condition in which naïve pancreatic stellate cells were cultured overnight in the presence of SB-431542 within intact D-ECM. **DMSO** treatment corresponds to vehicle control. Note that quantitative immunofluorescent obtained values of αSMA and F-actin were used to calculate stress fiber localization and expression of **αSMA**.

[^20]: P values, listed below, were calculated using the two-sided and two-tailed Mann Whitney test needed for normalized data.

[^21]: TGFβi vs. DMSO; p=0.3508 stress fiber localization; p=0.3361 expression.

[^22]: TGFβi vs. N-ECM (from [Table 1](#tbl1){ref-type="table"}); **p=0.0110** stress fiber localization; **p=0.0010** expression.

[^23]: TGFβi vs. D-ECM (from [Table 1](#tbl1){ref-type="table"}); p=0.9132 stress fiber localization; p=0.3401 expression.

[^24]: DMSO vs. N-ECM (from [Table 1](#tbl1){ref-type="table"}); **p=0.0036** stress fiber localization; **p\<0.0001** expression.

[^25]: DMSO vs. D-ECM (from [Table 1](#tbl1){ref-type="table"}); p=0.2635 stress fiber localization; p=0.7408 expression.

[^26]: Values obtained from naïve cells cultured overnight within intact D-ECMs treated with ALULA (**α~v~β~5~-i**), mAb16 (**α~5~β~1~-i**), ALULA plus mAb16 (**β~5~+α~5~-i**), SNAKA (**α~5~β~1~-act**) or control pre-immune antibody (**IgG**). Values obtained in untreated D-ECMs (from [Table 1](#tbl1){ref-type="table"}) were used for normalization and assigned an arbitrary unit of 1.00. Note that the quantitative values of αSMA and F-actin obtained by immunofluorescence were used to calculate stress fiber localization and expression of **αSMA**.

[^27]: P values, listed below, were calculated using the two-sided and two-tailed Mann Whitney test needed for normalized data.

[^28]: α~v~β~5~-i vs. IgG; **p=0.0001** stress fiber localization; **p=0.0002** expression.

[^29]: α~5~β~1~-i vs. IgG; p=0.1311 stress fiber localization; p=0.1229 expression.

[^30]: β~5~+α~5~-i vs. IgG; **p=0.0333** stress fiber localization; p=0.9171 expression.

[^31]: α~5~β~1~-act vs. IgG; **p=0.0047** stress fiber localization; **p=0.0020** expression.

[^32]: Values obtained from naïve renal fibroblastic cells cultured overnight within intact rD-ECMs (made from rCAFs) were used for normalization and assigned an arbitrary unit of 1.00. Assorted ECMs were intact r**N-ECM** or intact r**D-ECM,** while experimental conditions included D-ECMs made by CAFs treated with SB-431542 (r**D+TGFβi**) or DMSO (r**D+DMSO**) during ECM production. Experimental conditions during replating of naïve cells within rD-ECM also included treatment with SB-431542 (**TGFβi**) or vehicle (**DMSO**) as well as treatment with ALULA (**α~v~β~5~-i**), mAb16 (**α~5~β~1~-i**), ALULA plus mAb16 (**β~5~+α~5~-i**), SNAKA (**α~5~β~1~-act**) or control pre-immune antibody (**IgG**). Note that quantitative values for αSMA and F-actin immunofluorescence were used to calculate stress fiber localization and expression of **αSMA**.

[^33]: P values, listed below, were calculated using the two-sided and two-tailed Mann Whitney test needed for normalized data.

[^34]: rN-ECM vs. rD-ECM; **p\<0.0001** stress fiber localization.

[^35]: rN-ECM vs. rD+TGFβi; **p=0.0221** stress fiber localization.

[^36]: rN-ECM vs. rD+DMSO; **p\<0.0001** stress fiber localization.

[^37]: rD-ECM vs. rD+TGFβi; **p=0.0058** stress fiber localization.

[^38]: rD-ECM vs. rD+DMSO; p=0.1657 stress fiber localization.

[^39]: rD+TGFβi vs. rD+DMSO; **p=0.0630** stress fiber localization.

[^40]: TGFβi vs. DMSO; p=0.7996 stress fiber localization.

[^41]: TGFβi vs. rN-ECM; **p\<0.0001** stress fiber localization.

[^42]: TGFβi vs. rD-ECM; p=0.6560 stress fiber localization.

[^43]: DMSO vs. rN-ECM; **p\<0.0001** stress fiber localization.

[^44]: DMSO vs. rD-ECM; p=0.5042 stress fiber localization.

[^45]: α~v~β~5~-i vs. IgG; **p=0.0001** stress fiber localization.

[^46]: α~5~β~1~-i vs. IgG; **p=0.0008** stress fiber localization.

[^47]: β~5~+α~5~-i vs. IgG; ***p=0.0880*** stress fiber localization.

[^48]: α~5~β~1~-act vs. IgG; ***p=0.0665*** stress fiber localization.

[^49]: N/A: Not available.
